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 Zusammenfassung 
 
Invariante natürliche Killer T Zellen (iNKT Zellen), natürliche Killerzellen (NK Zellen) sowie 
Zytokin-induzierte Killerzellen (CIK Zellen) und ihre Untergruppen sind maßgeblich an der 
Immunüberwachung beteiligt. Vor kurzem wurde für die Detektion von iNKT Zellen der 
monoklonale Antikörper „6B11“ entwickelt, welcher die CDR3-Region der invarianten 
Vα24Jα18-Kette des T-Zell-Rezeptors (TCR) von iNKT Zellen erkennt.  
 
Im ersten Teil meiner Arbeit wurden iNKT, NK und CIK Zellen und deren Untergruppen in 
peripheren Blutproben von gesunden Spendern (n=9), Patienten mit akuter myeloischer 
Leukämie (AML; n=23), Patienten mit akuter lymphatischer Leukämie (ALL; n=20) und 
Patienten mit chronisch lymphatischer Leukämie (CLL; n=21) in akuten Krankheitsphasen 
untersucht und die Anzahl an iNKT, NK und CIK Zellen mit der Prognose der Patienten 
korreliert.  
 
Die wichtigsten Ergebnisse waren: 
 
I.1) Im Vergleich zu gesunden mononukleären Zellen (MNC) zeigten MNC von AML, ALL 
und CLL Patienten (signifikant) geringere Anteile an iNKT Zellen (6B11+/ 6B11+CD3+/ 
6B11+CD161+), NK Zellen (CD3-CD56+/ CD3-CD161+) und CIK Zellen (CD3+CD56+/ 
CD3+CD161+). 
 
I.2) In AML, ALL und CLL Patienten konnten im Vergleich zu Gesunden (signifikant) höhere 
Anteile an 6B11+ iNKT Zellen in der CD3+ T Zell- (iNKT Zellen vom „T Zell-Typ“) sowie in 
der CD161+ NK Zell-Fraktion (iNKT Zellen vom „NK Zell-Typ“) gefunden werden. 
 
I.3) Prognostisch günstige AML Untergruppen (Patienten unter 18 Jahren, primärer 
Krankheitsstatus, kein extramedullärer Befall, Erlangung und Erhaltung einer Vollremission 
(CR) nach Initialtherapie) korrelierten mit größeren Mengen an iNKT, NK und CIK Zellen. 
Ähnliche Zusammenhänge konnten auch bei (erwachsenen) ALL und CLL Patienten 
festgestellt werden. 
Im zweiten Teil meiner Arbeit wurden heparinisierte Vollblut- (WB) und MNC-Proben von 
gesunden Spendern (n=10), Patienten mit AML (n=5) und von einem Patienten mit  
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Myelodysplastischem Syndrom (MDS; n=1) untersucht. Diese Proben wurden in der Zellkultur 
mit verschiedenen „Cocktails“ vorbehandelt, die die Konversion von leukämischen Zellen zu 
Dendritischen Zellen leukämischen Ursprungs (DCleu, Leukämie-Antigenpräsentierende 
Zellen) induzieren. Als Kontrolle dienten unbehandelte, kultivierte WB- oder MNC-Proben. 
Sowohl unter Normoxie (mit 21% O2) als auch unter physiologischen hypoxischen 
Bedingungen (ca. 10% O2) wurden iNKT, NK und CIK Zellen und deren Untergruppen 
quantitativ und qualitativ vor und nach gemischter Lymphozytenkultur (MLC) mit T Zell-
angereicherten WB- oder MNC-Proben untersucht. Als „Stimulator-Fraktion“ dienten mit 
„Cocktails“ vorbehandelte oder nicht vorbehandelte WB- oder MNC-Proben, als Effektorzellen 
dienten mit T Zellen angereicherte immun-reaktive WB- oder MNC-Proben. Mit einem 
Zytotoxizitätsassay wurde die blasten-lytische Aktivität von iNKT, NK, CIK und T Zellen nach 
der MLC untersucht. 
Die wichtigsten Ergebnisse waren: 
II.1) iNKT, NK und CIK Zellen nahmen nach der MLC unabhängig von den verwendeten 
„Cocktails“ / „Stimulator-Zellsuspensionen“ (unter dem Einfluss von Interleukin-2 (IL-2)) zu.  
II.2) Die Vorbehandlung von WB oder MNC mit „Cocktails“ in der Zellkultur erhöhte die 
Anzahl von iNKT Zellen und veranlasste außerdem eine Verschiebung der Zusammensetzung 
der iNKT, NK und CIK Untergruppen nach der MLC, was mit einem verbesserten 
antileukämischen Potenzial korrelieren könnte.  
II.3) Nach der Vorbehandlung mit verschiedenen „Cocktails“ (vor allem Prostaglandin-
haltigen) zeigten individuelle WB- oder MNC-Proben variierende, jedoch höhere Zahlen an 
iNKT und CIK Zellen. 
II.4) Die DC, iNKT, NK und CIK Zell Werte nach der MLC waren unter physiologischen 
Hypoxie- und Normoxie-Bedingungen vergleichbar. 
II.5) Die Anzahl an T, iNKT, NK und CIK Zellen nach MLC korrelierte direkt mit 
antileukämischer, tumorlysierender Aktivität, was für eine Beteiligung dieser Zellen an 
antileukämischen Reaktionen spricht. 
Zusammenfassend konnte gezeigt werden, dass gesunde MNC signifikant höhere Mengen an 
iNKT, NK und CIK Zellen im Vergleich zu leukämischen AML, ALL und CLL MNC 
enthalten. Außerdem konnte demonstriert werden, dass Untergruppen von iNKT Zellen in 
gesunden und leukämischen MNC-Proben unterschiedlich zusammengesetzt sind. Des 
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Weiteren konnte dargelegt werden, dass die Anzahl an iNKT, NK und CIK Zellen mit der 
Prognose von AML, ALL und CLL Patienten korreliert. Darüber hinaus konnte gezeigt werden, 
dass „Cocktail“ behandelte AML Zellen (die zu DCleu umgewandelt wurden) nach MLC mit 
Effektorzellen (T Zell angereichterte MNC / WB) zu einer Verschiebung der Anzahl und 
Zusammensetzung von T, iNKT, NK und CIK Zellen führten. Dies korrelierte mit einer 
verbesserten antileukämischen Aktivität, was für eine Interaktion dieser Zellen spricht.  
 
Das bedeutet, dass die Anzahl an iNKT, NK und CIK Zellen (basierend auf der Detektion mit 
den Antikörpern 6B11, CD161, CD56 und CD3) regelmäßig bei AML, ALL und CLL Patienten 
im Rahmen eines diagnostischen Panels gemessen werden sollte, um eine quantitative, 
qualitative und prognostisch relevante Abschätzung des antileukämischen Potenzials des 
individuellen Patienten detailliert zu erfassen und um mehr über ihre Rolle in der DC und DCleu 
vermittelten Immunüberwachung zu lernen. 
Die Inhalte dieser Arbeite werden im „Journal of Immunotherapy“ publiziert (derzeit im 
Druck).  
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 Abstract 
 
Invariant natural killer cells (iNKT cells), natural killer cells (NKT cells) and cytokine 
induced killer cells (CIK cells) and their subsets are important for immune-surveillance. 
Recently, a new monoclonal antibody ‘6B11’ was developed for iNKT cell detection, which 
targets the Vα24Jα18 invariant T cell receptor (TCR) in the CDR3-region of iNKT cells.  
In the first part of my work iNKT, NK and CIK cells and their subsets were analysed in PB-
samples from healthy donors (n=9), patients with acute myeloid leukemia (AML; n=23), 
patients with acute lymphoid leukemia (ALL; n=20) and patients with chronic lymphoid 
leukemia (CLL; n=21) in acute disease-stages and findings were correlated with prognosis.  
The main results were:  
I.1) Compared to healthy mononuclear cells (MNC) (significantly) lower proportions of iNKT 
cells (6B11+/ 6B11+CD3+/ 6B11+CD161+), NK cells (CD3-CD56+/ CD3-CD161+) and CIK 
cells (CD3+CD56+/ CD3+CD161+) were found in MNC from AML, ALL and CLL patients.  
I.2) Compared to healthy MNC (significantly) higher proportions of 6B11+iNKT cells were 
found in the CD3+ T cell- (‘T cell-like’ iNKT cells) and in the CD161+NK cell fraction (‘NK 
cell-like’ iNKT cells) in AML, ALL and CLL patients. 
I.3) Prognostically favorable AML subgroups (patients younger than 18 years, primary 
disease-status, no extramedullary disease, achievement and maintenance of complete 
remission (CR) after induction-chemotherapy) showed higher proportions of iNKT, NK and 
CIK cells. Comparable correlations were seen in (adult) ALL and CLL patients. 
In the second part of my work heparinized whole blood-(WB) and MNC-samples from 
healthy donors (n=10), AML patients (n=5) and one patient with myelodysplastic syndrome 
(MDS; n=1) were analysed. Samples were pre-treated with different ‘cocktails’ in the cell 
culture, which induce the conversion of leukemic cells to dendritic cells of leukemic origin 
(DCleu, leukemia-antigen-presenting cells). Not pre-treated, cultured WB- or MNC-samples 
served as control. iNKT, NK and CIK cells and their subsets were quantitatively and 
qualitatively analysed before and after mixed-lymphocyte-cultures (MLC) of T cell enriched 
WB- or MNC-samples under normoxia (21% O2) as well as under physiological hypoxia 
(approx. 10% O2). ‘Cocktail’ pre-treated or not pre-treated WB- or MNC-samples served as a 
‘stimulator-suspension’, T cell enriched immune-reactive WB- or MNC-samples served as 
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effector cells. Blast-lytic activity of iNKT, NK, CIK and T cells after MLC was examined 
using a cytotoxicity (fluorolysis) assay.  
The main results were: 
II.1) iNKT, NK and CIK cells increased after MLC independent of the applied ‘cocktail’ / 
‘stimulator cell suspension’ (under the influence of IL-2). 
II.2) Pretreatment of MNC- or WB-samples with ‘cocktails’ in the cell culture increased 
frequencies of iNKT cells and led to a shift in the composition of iNKT, NK and CIK cell 
subsets after MLC, what might correlate with an improved antileukemic potential. 
II. 3) Individual samples showed varying, however higher iNKT and CIK cell frequencies 
after pretreatment with different (especially prostaglandin-containing) ‘cocktails’. 
II.4) DC, iNKT, NK and CIK cell values after MLC were comparable in physiological 
hypoxia vs normoxia.  
II.5) Frequencies of T, iNKT, NK and CIK cells after MLC correlated directly with 
antileukemic, blast-lytic activity – pointing to an involvement of these cells in antileukemic 
reactions.  
In summary, healthy MNC presented with significantly higher iNKT, NK and CIK cells 
compared to leukemic AML, ALL and CLL MNC. Moreover, subtypes of iNKT cells differ 
in healthy vs leukemic samples. Furthermore, frequencies of iNKT, NK and CIK cells 
correlated with prognosis of patients with AML, ALL and CLL. In addition, ‘cocktail’ pre-
treated AML-blasts (resulting in DCleu) after MLC with effector cells (T cell enriched WB / 
MNC) led to a shift in T, iNKT, NK and CIK cell counts and compositions. These findings 
correlated with improved antileukemic activity against AML-blasts - pointing to a cross-talk 
of these cells. 
Proportions of iNKT, NK and CIK-cells (based on detection with 6B11/ CD161/ CD56/ CD3 
antibodies) should regularly be evaluated in AML, ALL and CLL diagnosis-panels for 
quantitative, qualitative and prognostically relevant estimation of individual pts’ antileukemic 
potential in detail and to learn about their role in DC/DCleu triggered immune-surveillance.  
The contents of this work will be published in the “Journal of Immunotherapy” (in press). 
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 Introduction 
 
3.1 Acute myeloid, acute lymphoid and chronic lymphoid leukemia 
 
Acute myeloid (AML), lymphoid (ALL) or chronic lymphoid leukemia (CLL) are clonal 
diseases with uncontrolled proliferation of myeloid or lymphoid blasts. Prognostic rates of 
complete remission and survival depend on grade of anemia, thrombocytopenia, white blood 
cell expansion and karyotypes, resulting in different therapeutic strategies. Therapy for AML, 
ALL and CLL patients with advanced stages consists of chemotherapy and stem cell-
transplantation (SCT), but the rate of early failures and relapses is still unsatisfying. AML 
patients can be categorized into 3 risk groups.1 ALL patients are primarily children with 
survival rates of about 90% and higher incidences for an assignment to standard risk-groups 
compared to adult patients with higher tendencies for high risk leukemia.2 CLL usually occurs 
in elderly patients and these are classified in Binet-staging groups: Binet A (early), B 
(intermediate) and C (advanced stage).3  
 
3.2 T, iNKT, NK, CIK cells and DC/ DCleu and their role in immune surveillance 
 
Effective immune surveillance of patients with hematologic malignancies such as leukemia is 
mediated by arms of the innate and adaptive immune system. The innate immune system 
includes macrophages, dendritic cells (DC) and natural killer (NK) cells, which respond quickly 
to an immunological threat.4 NK cells have the ability to kill tumor cells without activation, 
arise from CD34+ bone marrow (BM) cells and are defined as CD3-CD56+CD161+.5 The 
adaptive immune system includes T and B cells, which mediate tumor immunity by antigen-
specific responses and provide long lasting protection by effector-memory responses. T-cells 
(CD3+) express T-cell-receptors (TCR) that recognize (peptide-) antigens on blasts, which have 
to be presented by MHC-I- or MHC-II- (major-histocompatibility-complex) molecules via 
antigen presenting cells (APCs).4 A specialty of myeloid blasts is, that they can differentiate to 
leukemia-derived dendritic cells (DCleu), presenting the complete leukemic antigen repertoire, 
thereby specifically and efficiently activating an antileukemic T cell response.6-8 T cells occur 
in various differentiation- and functional subsets (e.g.: naive (Tnaive, CD45RO
-), non-naive 
(Tnon-naïve, CD45RO
+), central-memory (Tcm, CD45RO
+CCR7+), effector/memory (Teff-em, 
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CD45RO+CCR7-) and regulatory (Treg, CD25
++CD127+low)).9,10 Furthermore, other cells at the 
interface of the innate and the adaptive immune system are important mediators in antitumor-, 
autoimmune- and antimicrobial responses and tumor surveillance4: Cytokine-induced killer 
(CIK) cells have phenotypic and functional features of T  and NK cells as they are 
CD3+CD56+CD161+, they are expandable in culture like T cells, however they do not recognize 
cells via T cell receptor or MHC molecules as T cells.5 NKT-cells are a heterogeneous lymphoid 
population, that bridge innate and adaptive immunity and, in general, share properties of T and 
NK cells. Similar to NK cells, NKT cells have the ability to react rapidly to antigenic 
stimulation by quickly secreting large amounts of cytokines and chemokines within minutes to 
hours.4 In addition, they activate DC, NK and CD4+/CD8+T cells, thereby triggering innate and 
adaptive immune responses.11 Similar to T cells, NKT cells respond via the TCR, recognizing 
glycolipid antigens presented by the MHC-like molecule CD1d. TCR from NKT cells react 
with many self  and foreign antigens, while the TCR from T cells only reacts with one epitope.4 
It was shown that the positive selection of NKT cells is strictly dependent on CD1d during 
ontogeny in the thymus and therefore CD1d restriction has become the defining characteristic 
of NKT cells (NK markers are only used to define subpopulations).12 The NKT cell population 
consists of many phenotypically and functionally diverse subsets, which are subdivided either 
by surface markers, TCR, tissue-location, antigen recognition or by effector functions. 
Concerning their heterogeneous TCR rearrangements, NKT cells are divided into two main 
groups: Type-I NKT cells are referred to as invariant NKT cells (iNKT cells) as they express a 
semi-invariant TCR, characterized in humans by Vα24-Jα18 and Vβ11, while ß-chains have a 
limited variety. On the other hand, NKT cells that do not express this semi-invariant TCR are 
referred to as Type-II NKT cells, which are less well studied than iNKT cells.11 iNKT cells are 
known for enhancement of tumor immunity, while Type-II NKT cells are known for 
suppression of it, resulting in opposed roles in tumor immunity and cross-regulate of each 
other.4  
 
3.2.1 Origin of iNKT-cells 
 
NKT cells originate from a precursor pool of CD4+CD8+ double positive (DP) thymocytes that 
have to undergo diverse TCR gene rearrangements, are then positively selected by CD1d+ DP 
thymocytes in the thymic cortex, undergo four differentiation and maturation steps and then 
differentiate into mature NKT cells. Expression of  CD4 and CD8 allow a subdivision of NKT 
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cells in different subpopulations: A majority is CD4+ (90% in mice), the remainder is CD4-
CD8- double negative (DN) and a small population is CD8αα+ and CD8αβ+, but CD8+subsets 
only exist in humans (not in mice), predominantly in healthy persons with latent EBV 
infection.12  
 
3.2.2 Detection methods of iNKT cells 
 
The evaluation of human iNKT cells is challenging, as their frequency in peripheral blood (PB) 
is very low. Classically, iNKT cells have been identified using CD1d tetramers loaded with α-
galactosylceramide (α-GalCer) or monoclonal antibodies (moAbs) against the Vα24- and 
Vβ11-chains, what however, can lead to an overestimation of iNKT cells, as non-invariant, non-
CD1d restricted Vα24+ T cells can also pair with Vß11. Recently iNKT cells were shown to be 
identified using the moAb 6B11, which recognizes the invariant CDR3 loop of their Vα24Jα18 
TCR-rearrangement with high specificity and sensitivity.13 CD161 (NKR-P1A) is a C-type 
lectin receptor and is an important marker for NK and iNKT cell identification since all human 
NK cells, high proportions of iNKT cells and Teff/em and Tcm express it.  Recently it was shown 
that CD161+ T cell subsets are highly functional during infections: Low frequencies correlate 
with higher incidence of (viral) infections.14-16 17,18 
 
3.3 Stimulation by DC/DCleu 
 
Considering that the antileukemic function of T cells can be stimulated by leukemia-derived 
DC (DCleu)
9,10, our supposion is that the iNKT/ NK and CIK cell activity might also be enhanced 
under DC/ DCleu-stimulation. DCleu can be generated in vitro by converting myeloid leukemia 
cells in mononuclear cells (MNC) or whole blood (WB) using DC-generating methods/Kits 
(‘Cocktails’, containing immune-response-modifiers in combination with cytokines) and 
represent as well leukemic (e.g.: CD13, CD33, CD117) and DC antigens (e.g.: CD80, CD83, 
CD86).19,20  
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3.4 Influence of hypoxic conditions on immune-reactive cells  
 
Physiological conditions in the stem-cell niche of the BM as well as in the PB are hypoxic with 
Oxygen (O2) concentrations between 0.1 to 0.6 % in the BM, 12% in arterial blood and 4-15% 
in PB.21,22 Previous studies suggest an influence of the oxygen partial pressure (pO2) on several 
pathophysiological mechanisms.23,24 However, hematopoiesis takes place under 
physiologically low pO2/ O2 concentration and hematopoietic cells are continually exposed to 
dynamic pO2 values.
25 Moreover, a recent in vitro study showed that hypoxia might have an 
enhancing effect on NK cells.26  
 
3.5 Objectives of this study 
 
The aim of this study was  
 
1) to test the suitability of different markers and combinations to characterize and quantify 
iNKT, NK and CIK cells and subsets,  
 
2) to quantify iNKT, NK and CIK subsets in MNC from patients with AML, ALL and CLL 
compared to healthy controls, 
 
3) to correlate findings with disease entities and prognostic subgroups, 
 
4) to quantify iNKT, NK and CIK subsets as well as T cells under stimulation with DC/ DCleu 
that are generated from WB or MNC with various ‘cocktails’. 
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 Material and Methods 
 
Sample preparations and evaluations, characterization of cells by fluorescence-activated cell-
sorting Flow-Cytometer and Cell-Quest-data-acquisition and analysis-software as well as 
statistical analyses of our results were carried out by me.  
Part of the experimental work from the first part of the experiments was performed by cand. 
Dr. med. Wishnu Sutanto and Dr. med. dent. Thomas Guenther, who have both been working 
in the laboratory of Prof. Dr. rer. nat. Helga Schmetzer (University Hospital of Munich, 
Department of Hematopoetic Cell Transplantation, Medical Department 3).  
Part of the experimental work from the second part of the experiments was fulfilled by cand. 
Dr. med. Daniel Christoph Amberger and cand. Dr. rer. biol. hum. Fatemeh Doraneh-Gard, who 
are working in the laboratory of Prof. Dr. rer. nat. Helga Schmetzer (University Hospital of 
Munich, Department of Hematopoetic Cell Transplantation, Medical Department 3).  
Clinical data of the patients were provided by Dr. med. Joerg Schmohl (Universtiy Hospital of 
Tuebingen, Department of Hematology and Oncology), Dr. med Schuster (University Hospital 
of Duesseldorf, Department of Pediatric Hematology, Oncology and Clinical Immunology) and 
physicians of the University of Munich, Augsburg and Oldenburg.   
 
4.1 Sample Collection  
 
After obtaining informed consent, heparinized peripheral WB samples were taken from patients 
in acute phases of AML, ALL, CLL and from healthy controls. MNC were prepared from WB 
samples by density gradient centrifugation using the Ficoll-Hypaque-technique (Biocoll-
Separating-solution, Biochrom, Berlin, Germany) with a density gradient of 1.077 g/ml. MNC 
were washed and suspended in phosphate-buffered saline (PBS, Biochrom, Berlin, Germany). 
CD3+ T cells were enriched using the MACS-technology (Milteney Biotech, Bergisch 
Gladbach, Germany). The purity of CD3+ T cells was on average (Ø) 89% (range 69-98%). 
Cells were quantified using Neubauer-counting-chambers, used directly or frozen and thawed 
according to standardized protocols. 
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4.2 Patients´ characteristics and diagnostics 
 
4.2.1 Patients and samples included for surface marker expression analyses on thawed cells 
 
Quantitative and qualitative characterizations of several immune reactive cells were performed 
with thawed MNC from patients with blast-rich phases of AML (n=23), ALL (n=19) and CLL 
(n=21). Samples were provided by the University-Hospitals of Tubingen, Dusseldorf, Munich, 
Oldenburg and Augsburg. Cells were obtained by aspirates of peripheral blood (PB) or bone 
marrow (BM), which were anticoagulated with heparin after patients’ written informed consent 
in accordance with the Helsinki protocol and the local Ethic Committee (Pettenkoferstr. 8a, 
80336 München, Ludwigs-Maximilians-University Hospital in Munich; Vote-No 339-05). The 
mean age of AML patients was 50 (range 23-81) years, of ALL patients 22 (range 3-50) years 
and of CLL patients 57 (range 33-72) years. The female to male ratio of AML patients was 
1:1.9, of ALL patients was 1:1.7 and of CLL patients was 1:0.9. 
 
Diagnosis and classification of AML patients (Table 1) was based on the ‘French-American-
British” (FAB) classification: minimally differentiated AML (M0: n=1), AML without 
 
Table 1: Uncultured AML samples studied for proportions and co-expression of iNKT, NK 
and CIK cells 
 
f=female; m=male; n.d.=no data; PB=peripheral blood; dgn =first diagnosis; pers.=persisting disease; rel.a.SCT = relapse after stem cell 
transplantation; ind. chemo. = induction chemotherapy; 1complete remission (CR) achieved or not achieved (NCR) after treatment with SCT; 
2at dgn.; bold letter= antibodies used for (co)expression analyses 
Age at Cell Risk score Resp. to Resp. to 
Pat. # dgn./Sex Subtype Stage Source Blast phenotype (CD) Blasts % Cytogenetic marker at dgn. (NCCN) SCT ¹ ind. chemo.
P1050 32/f s/M1 dgn. PB 117,33,13 78 46,XX n.d. CR n.d.
P1053 25/m p/M1 rez. PB 117,34,33,56 65 n.d. n.d. NCR n.d.
P1056 27/m p/M4 dgn. PB 117,34,33,13,15 53 46,XY n.d. n.d. CR
P1057 32/m p/M5 dgn. PB 117,34,33,13,14,15,38,2 39 inv(16)pq, +22 favorable n.d. n.d.
P1058 71/m p/M1 dgn. PB 117,34,33,13,15,38,45,71,w65 91 +11 intermediate n.d. n.d.
P1059 66/m p/M4 dgn. PB 117,34,33,13,7 84 del(5)qq, add(17)p, add(21)q, der(9) adverse n.d. CR
P1060 81/f s/n.d. dgn. PB 117,34,33,13 97 n.d. n.d. n.d. n.d.
P1061 62/f p/M0 rel. a. SCT PB 117,34,33,13 96 46,XX intermediate NCR n.d.
P1062 41/f p/M4 dgn. PB 117,34,33,13,14,15,71 61 t(6;9)pq, add(21), -7, del(8), del(15), +mar adverse n.d. NCR
P1063 26/m p/M5 rel. a. SCT PB 117,34,2 86 n.d. n.d. n.d. n.d.
P1066 60/m s/M2 dgn. PB 117,34,33,65 74 46,XY adverse n.d. n.d.
P1067 27/m p/M4eo dgn. PB 117,34,33,13,15,65 41 inv(16)pq, +8 favorable n.d. CR
P1068 76/m p/M2 dgn. PB 117,34,33,13 39 n.d. intermediate n.d. n.d.
P1069 33/m p/M4eo dgn. PB 117,34,33,13,15 61 inv(16)pq, t(12;17)pq favorable n.d. CR
P1071 71/f s/M1 dgn. PB 117,34,33,13,15 60 +4 intermediate n.d. CR
P1072 58/m p/M2 pers. PB 117,34,33,13 70 -4,-5,-7,-11,-12,-14,-16,-21,+mar adverse n.d. NCR
P1073 23/m p/M5 dgn. PB 117,34,33,13,15,7,65 18 +8,+13 intermediate n.d. n.d.
P1076 47/f s/M1 dgn. PB 117,34,33,13,14 99 +8 intermediate CR CR
P1077 41/f p/M1 dgn. PB 117,34,33,13,15,7 71 del(12)p intermediate CR CR
P1078 73/m p/M2 dgn. PB 117,34 84 46,XY intermediate n.d. n.d.
P1083 41/m p/M2 dgn. PB 117,133,33,13,65 43 46,XY intermediate CR CR
P1084 55/m p/M4 dgn. PB 117,33,13,71 84 46,XY intermediate n.d. CR
P1085 71/f p/M2 dgn. PB 117,33,56 96 46,XX intermediate n.d. n.d.
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maturation (M1: n=6), AML with granulocytic maturation (M2: n=6), acute myelomonocytic 
leukemia (M4: n=4), acute myelomonocytic leukemia together with BM- eosinophilia (M4eo: 
n=2), acute monocytic leukemia (M5: n=3). Pts presented with pAML (n=18) or with sAML 
(n=5). Patients stages were: first diagnosis (n=20), relapse before (n=1) or after SCT (n=2). 
Patients were classified in cytogenetic risk groups based on the National Comprehensive Cancer 
Network (NCCN) guidelines as ‘favorable’ (n=3), ‘intermediate’ (n=11) or ‘adverse risk’ 
(n=4); for five patients, no further data were available. 
The subtypes of the 19 ALL (Table 2) patients were immune cytologically classified according 
to the European Group for Immunophenotyping of Leukemias (EGIL) classification: pro B 
ALL (BI:n=1), c ALL (BII:n=5), pre B ALL (BIII:n=2), My+c ALL (BII+My:n=3), My+pre B 
ALL (BIII+My:n=1), pro T ALL (TI:n=1), pre T ALL (TII:n=1), cortical T ALL (TIII:n=4), 
mature T ALL (TIV:n=1). Patients presented with pALL (n=5) or with sALL (n=14). Stages of 
samples were: diagnosis before SCT (n=17) or at relapse after SCT (n=2). Risk stratification of 
adult ALL was based on the Study-Group for Adult Acute Lymphoblastic Leukemia (GMALL) 
as ‘standard’ (n=3), ‘high’ (n=1) or ‘highest risk’ (n=3); for 12 patients no further data were 
available.  
 
Table 2: Uncultured ALL samples studied for proportions and coexpression of iNKT, NK 
and CIK cells 
 
f=female; m=male; n.d.=no data; PB=peripheral blood; dgn =first diagnosis; pers.=persisting disease; rel.a.SCT = relapse after stem cell 
transplantation; ind. chemo. = induction chemotherapy; 1complete remission (CR) achieved or not achieved (NCR) after treatment with SCT; 
bold letter= antibodies used for (co)expression analyses 
Age at Cell Risk Score Resp. to Resp. to
Pat. # dgn./Sex Subtype Stage Source Blast phenotype (CD) Blasts % Cytogenetic marker at dgn.(GMALL) SCT ¹ ind. chemo.
P1106 24/f p/BII+My dgn. PB 34,19,33,133,13 81 46,XX high risk n.d. CR
P1107 31/m s/BII+My dgn. PB 34,19,33,10,24 36 t(9;11)qq highest risk n.d. CR
P1108 32/m s/TIII dgn. PB 5,2,1a,15,cy3 98 46,XY standard n.d. CR
P1109 21/m p/BII+My dgn. PB 34,19,33,13,10,38 85 46,XY standard n.d. CR
P1110 50/f p/BIII+My dgn. PB 34,133,33 59 t(9;22)qq, der(22) highest risk n.d. CR
P1111 26/m s/BII rel. a. SCT PB 34,19,10 64 del(11q) n.d. n.d. n.d.
P1112 37/m s/BII rel. a. SCT PB 34,19,10 17 n.d. n.d. n.d. n.d.
P1113 64/f /B rez./pers. PB 34,19,15 n.d. n.d. n.d. n.d.
P1114 22/m p/BIII dgn. PB 19,20,34,38 97 46,XY highest risk n.d. CR
 ALL P1115 45/m p/TIII dgn. PB 5,7,38,71 99 46,XY standard n.d. CR
P1120 20/m s/TII dgn. PB 19,5,34,20,3 28 46,XY n.d. CR n.d.
P1121 25/f s/BI dgn. PB 34,19, 33 32 n.d. n.d. n.d. n.d.
P1122 23/m s/TIII dgn. PB 4,8,1,2,5,7 86 46,XY
P1129 11/m s/BII dgn. BM 34,19,10,22 85 46,XY n.d. n.d. CR
P1132 12/m s/BIII dgn. BM 19,10,22 84 n.d. n.d. n.d. CR
P1133 3/f s/BII dgn. BM 34,19,10,22 55 46,XX n.d. n.d. CR
P1135 17/m s/TI dgn. BM 34,7,4,5,10,13,33 98 46,XY n.d. n.d. CR
P1136 5/f s/TIII dgn. PB 34,7,1a,2,3,5,10 82 46,XX n.d. n.d. CR
P1137 3/f s/BII dgn. BM 34,10,19,22 71 46,XX n.d. n.d. CR
P1146 8/f s/TIV dgn. PB 7,3,1,34 98 46,XX n.d. n.d. CR
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All CLL patients (Table 3) were classified as pB-CLL (n=21) at diagnosis (n=2) or with 
persisting disease (n=19). Risk stratification was based on the Binet-classification: Binet A 
(n=14), Binet B (n=6) or Binet C (n=1).  
 
Table 3: Uncultured CLL samples studied for proportions and coexpression of iNKT, NK 
and CIK cells 
 
f=female; m=male; n.d.=no data; PB=peripheral blood; dgn =first diagnosis; pers.=persisting disease; rel.a.SCT = relapse after stem cell 
transplantation; th. = therapy; 1complete remission (CR) achieved or not achieved (NCR) after treatment with SCT; 2at dgn.; bold letter= 
antibodies used for (co)expression analyses 
 
4.2.2 Cell-lines included for surface marker analyses 
 
The following cell lines (Table 4) were studied for surface marker profiles: HL-60 (AML-M2), 
OCI-AML2 (AML-M4), Mono-Mac 6 (AML-M5), THP-1 (AML-M5), MOLM (AML-M5a), 
RAMOS (B-ALL–L3), RAJI (B-ALL–L3) and JURKAT (T-ALL). Cell lines were purchased 
from the American Type Culture Collection (ATCC) and cultured according to manufacturer’s 
instructions. 
 
 
Age at Cell Risk Score Resp. to Need for
Pat. # dgn./Sex Subtype Stage Source Blast phenotype (CD) Blasts % Cytogenetic marker at dgn.(BINET) SCT ¹ initial. th.
P1088 44/f p/B-CLL pers. PB 5,19,20 98 n.d. A n.d. yes
P1089 54/m p/B-CLL pers. PB 5,19 95 n.d. B n.d. yes
P1090 43/m p/B-CLL dgn. PB 5,19,kappa 95 add(1)q, del(9)q,del(11)qqA n.d. yes
P1091 68/m p/B-CLL pers. PB 5,19,20 96 del(13)q A n.d. no
P1092 66/m p/B-CLL pers. PB 5,19,20 71 n.d. B n.d. no
P1093 51/f p/B-CLL pers. PB 5,23,kappa 94 n.d. A n.d. no
P1094 67/m p/B-CLL pers. PB 5,19,kappa 91 n.d. A n.d. no
P1095 65/f p/B-CLL pers. PB 5,19 88 del(13)q A n.d. yes
P1096 64/m p/B-CLL pers. PB 5,19,lambda 95 n.d. A n.d. no
P1097 72/f p/B-CLL pers. PB 5,19,20,22,kappa 97 n.d. A n.d. yes
 CLL P1098 60/f p/B-CLL pers. PB 5,19,kappa 93 n.d. B n.d. no
P1099 67/m p/B-CLL dgn. PB 5,19,20,23,lambda 89 n.d. A n.d. no
P1100 36/m p/B-CLL pers. PB 5,19,lambda 91 del(17)p, der(11)q B n.d. yes
P1101 52/m p/B-CLL pers. PB 5,19,20 96 n.d. A n.d. yes
P1102 45/f p/B-CLL pers. PB 5,19 91 del(13)q A n.d. yes
P1103 67/f p/B-CLL pers. PB 5,19,20 87 del(17)q A n.d. yes
P1104 66/f p/B-CLL pers. PB 5,19,kappa 94 n.d. A n.d. yes
P1116 66/f p/B-CLL pers. PB 5,19,kappa 96 t(8;13)qq A n.d. yes
P1117 33/m p/B-CLL pers. PB 5,19,23,kappa 40 del(13)q B n.d. yes
P1118 60/f p/B-CLL pers. PB 5,19,20,22,23,kappa 32 del(11)q C n.d. yes
P1119 55/f p/B-CLL pers. PB 5,19,20,22,23,38,kappa 57 n.d. B CR yes
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Table 4: Cell lines and their origin 
 
f=female; m=male; n.d.=no data; PB=peripheral blood; bold letter= antibodies used for (co)expression analyses 
 
4.2.3 AML patients and samples included for culture-experiments 
 
Cellular composition of immune reactive cells in MNC or WB samples from 5 AML patients, 
1 MDS patient and from 10 healthy volunteers were studied before or after culture with/without 
DC/DCleu-generating strategies or mixed lymphocyte culture (MLC) with (T) cells from the 
patients (Table 5).  
 
Table 5: AML-samples used for culture experiments in hypoxia vs. normoxia 
f=female; m=male; n.d.=no data; PB=peripheral blood; dgn. = first diagnosis; rez. = relapse; FAB = “French-American-British” classification; 
bold letter= antibodies used for (co)expression analyses 
 
 
Cell cultures were either performed under ‘normoxic conditions’ (37°C, 5% CO2 and 21% O2). 
Further we studied the influence of hypoxia on the composition and function of different 
immune reactive cells and cultured samples in parallel under ‘hypoxic conditions’ (37°C, 5% 
CO2 and with either varying O2-concentrations between 0-17% during the incubation time in 
some cases or with a defined O2-concentration of 6 or 10%) using an InVivo400 working station 
(Ruskinn Technology, Bridgend, United Kingdom). 
Age Cell
Name /Sex Subtype Cell type Source Blast phenotype (CD)
HL-60 35/f FAB M2 AML PB 33,13,15
OCI-AML2 65/m FAB M4 AML PB 13,14,15,33,4
THP-1 1/m FAB M5 AML PB 33,13,14,15
Mono-Mac-6 64/m FAB M5 AML PB 13,14,15,33,68
MOLM-13 20/m FAB M5a AML PB 33,13,15,4
RAMOS 3/m B-lymphoblastic Burkitt lymphoma ascitic fluid 19,10,20,37,38,80
RAJI 11/m B-lymphoblastic Burkitt lymphoma left maxilla 20,10,13,19,37
JURKAT 14/m my
+ 
T-linear T-ALL n.d. 33,13,2,3,4,5,6,7,34
Age at Subtype Cell
Pat. # dgn./Sex (FAB) Stage Source Blast phenotype Blasts % Cytogenetic marker at dgn.
P1424 37/f p/M4 rez. PB 117,13,33,45 30 46,XX 
P1426 61/f p/M5 dgn. PB 34,117,13,33,64 40 n.d.
P1430 79/m p/M5/M6 dgn. PB 34,13,33,117 70 46,XY 
P1433 59/m p/MDS (RAEB-II) dgn. PB 34,13,15 18 n.d.
P1434 61/f s/n.d. dgn. PB 34,117,64,56,33,13,7 61 46,XX, t(3;8)
P1439 61/f s/M5 dgn. PB 34,117,13,33 9 inv(16)
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4.3 DC generation from isolated MNC or WB 
 
DC/ DCleu were generated from 4-5x10
6 isolated MNC from healthy volunteers or AML/MDS 
patients in blast-rich stages of the disease as described previously by others or us19,27 using Kit-
D, ‘Pici1’ or ‘Pici2’ (Table 6). 
 
Table 6: Overview of the different DC-generating methods/Kits (‘cocktails’) 
GM-CSF granulocyte-macrophage-colony-stimulating factor; IL-4 interleukin 4; OK-432 Picibanil; PGE2 prostaglandin E2; PGE1 
prostaglandin E1; references 
19,20,29 
 
Therefore, cells were pipetted into 12-multiwell-tissue-culture-plates (ThermoFisher Scientific, 
Darmstadt, Germany) and were diluted in 2ml serum free X-Vivo15-medium (Lonza, Basel, 
Swiss). 
Moreover, DC/ DCleu were generated from WB (presenting the physiological cellular and 
soluble composition of the individual samples) obtained from AML/MDS patients in blast-rich 
stages of the disease or from healthy volunteers.20,28 500µl WB was pipetted in 12-multiwell-
'Picibanil 1' GM-CSF GM-CSF: induction of myeloid 
('Pici1') IL-4 (DC-) differentiation
OK-432
PGE2
'Picibanil 2' GM-CSF IL-4: induction of DC-differentiation
('Pici2') IL-4
OK-432
PGE1 Picibanil (OK-432): lysis product from
Kit-D GM-CSF streptococcus pyogenes; stimulates 
(D) OK-432 DC-differentiation
PGE2
Kit-I GM-CSF PGE2: increases CCR7-expression 
(I) OK-432 and enhances migration
Kit-K GM-CSF
(K) PGE2
Kit-M GM-CSF PGE1: effects are comparable to PGE2 
(M) PGE1
7-10 days
7-10 days
7-10 days
7-10 days
7-10 days
7-10 days
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plates and diluted 1:2 in X-Vivo15-medium to imitate the physiological conditions. DC were 
generated from WB using six different DC-generating methods: ‘Pici1’, ‘Pici2’, Kit-D, -I, -K 
and -M (Table 6). A patent was written to save the idea of Kit-compositions (102014014993.5, 
German Patent Office), but no financial conflicts of interest have to be declared. In the 
subsequent chapters, we summarize all DC-generating methods and Kits under the term 
‘cocktails’. WB/MNC cultures without added response modifiers severed as a control. All 
substances used for the DC-generation are approved for human treatment. 
DC-subtypes were quantified as described in the chapter ‘cell characterization by flow 
cytometry’.20,28 
 
4.3.1 ‘Picibanil 1’ (‘Pici 1’) 
 
DC were generated from MNC or WB with the DC-generating protocol ‘Pici1’-containing 
500U/ml granulocyte macrophage colony stimulation factor (GM-CSF, Sanofi-Aventis, 
Frankfurt, Germany) and 250U/ml Interleukin-4 (IL-4) (PeproTech, Berlin, Germany). After 6-
7 days, 10µg/ml Picibanil (OK 432) - a lysis product from Streptococcus pyogenes which has 
unspecific immune modulatory effects (Chugai Pharmaceutical Co., Kajiwara, Japan) and 
1µg/ml Prostaglandin E2 (PGE2) (PeproTech, Berlin, Germany) were added.
19,29 After 7-10 
days of incubation cells were harvested and used for further experiments. 
 
4.3.2 ‘Picibanil 2’ (‘Pici 2’) 
 
DC were generated from MNC or WB with the ‘Pici2’-DC-generating-protocol - a protocol 
developed by our group, with the same composition as given above for ‘Pici1’, however 
substituting PGE2 by PGE1 (PeproTech, Berlin, Germany). 
 
4.3.3 Kit-D 
 
The generation of DC from MNC or WB with Kit-D was performed using 800U/ml GM-CSF, 
10µg/ml Picibanil and 1µg/ml PGE2 
20. After 2-3 days, the same amounts of cytokines were 
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added and after in total 7-10 days of incubation cells were harvested and used for subsequent 
experiments. 
 
4.3.4 Kit-I 
 
DC were generated with Kit-I using 800U/ml GM-CSF and 10µg/ml Picibanil20. Incubations 
were performed in analogy to Kit-D. 
 
4.3.5 Kit-K 
 
Kit-K consisted of 800U/ml GM-CSF and 1µg/ml PGE2 
20. Incubations were performed in 
analogy to Kit-D. 
 
4.3.6 Kit-M 
 
For the generation of DC with Kit-M, 800U/ml GM-CSF and 1µg/ml PGE1 were added to the 
culture 20. Incubations were performed in analogy to Kit-D. 
 
4.4 Mixed-lymphocyte-culture (MLC) of T cell enriched immune reactive cells with 
‘cocktail’ pretreated or not pretreated stimulator cell suspensions from MNC or WB 
 
Immune reactive cells were enriched with 1x106 positively selected CD3+ T cells (effector cells) 
from AML patients or healthy controls and co-cultured in 24-multiwell-tissue-culture-plates 
(ThermoFisher Scientific, Darmstadt, Germany) with a stimulator cell suspension containing 
2.5x105 DC/ DCleu (MLC
*‘MNC-DC’ or MLC*‘WB-DC’ which were generated with different 
‘cocktails’. The same setting, but with a stimulator cell suspension without pretreatment with 
‘cocktails’ (MLC*‘MNC’ or MLC*‘WB’) severed as a control. In one parallel tested case the 
stimulator cell suspensions were irradiated with 33Gy to inactivate residual immune reactive 
cells (e.g. iNKT/ NK and CIK cells). The total volume of the cell culture was adjusted to 1ml 
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with RPMI-1640 medium (Biochrom, Berlin, Germany) containing 1% Penicillin (Biochrom, 
Berlin, Germany) and 50U/ml IL-2 (PeproTech, Berlin, Germany). The MLC*‘MNC’ or 
MLC*‘MNC-DC’ further contained 15% human serum (Healthcare Europe GmbH, Vienna, 
Austria). After 2-3 days 50U/ml IL-2 were added to the WB- and MNC-cultures. Half-medium-
exchange for MNC-cultures was carried out every 2-3 days. Cells were harvested after 6-9 days 
and were used for the cytotoxicity fluorolysis assay as described below.  
Before and after culture different cell-subsets in the MNC and WB fractions were quantified by 
flow cytometry (Table 7). 
 
4.5 Cell characterization by flow cytometry  
 
Flow cytometric analyses were carried out to evaluate and quantify amounts, subsets and 
phenotypes of leukemic cells, B, T, iNKT, NK and CIK cells, monocytes and DC in the MNC 
and WB fractions before and after different cultures. Panels with several moAbs labeled with 
Fluorescein isothiocyanat (FITC), phycoerythrin (PE), tandem Cy7-PE conjugation (Cy7-PE), 
or allophycocyanin (APC) were used. Antibodies were provided by Beckman Coulter, Krefeld, 
Germany (a), Becton Dickinson, Heidelberg, Germany (b), Biozol, Eching, Germany (c), Caltag, 
Darmstadt, Germany (d), Bioscience, Heidelberg, Germany (e), Miltenyi Biotech, Bergisch 
Gladbach, Germany (f) and ThermoFisher Scientific, Darmstadt, Germany (g). FITC-
conjugated moAbs against CD3a, CD8b, CD33a, CD34a, CD45ROa, CD83a, CD161b, 6B11c and 
Vα24a were used. We used PE-conjugated moAbs for CD1de, CD3a, CD4b, CD34a, CD80a, 
CD83a, CD117a, CD206a and 6B11b. MoAbs against CD3a, CD4a, CD5a, CD14b, CD15b, 
CD19a, CD34a, CD80b, CD117a and CD197b were labeled with Cy7-PE. As APC-labeled 
moAbs we used CD1aa, CD3a, CD4a, b, CD5a, CD7e, CD8b, CD10a, CD14a, CD15b, CD19a, 
CD20a, CD33a, CD34a, d, CD45ROd, CD56a, CD69b, CD86g, CD117a, CD133f, CD206b and 
CD209b. To detect dead cells 7AADb was used. 
Erythrocytes in WB samples were lysed using Lysing-Buffer (BD, Heidelberg, Germany) 
according to manufacturer’s instructions. To stain cells (MNC or WB) with moAbs they were 
resuspended in PBS (Biochrom, Berlin, Germany), containing 5-10% fetal calf-serum (FCS, 
Biochrome, Berlin, Germany) to avoid unspecific bindings and were incubated for 15 minutes 
in the dark at room-temperature. Afterwards cells were washed, centrifuged and resuspended 
in 100-200µl PBS. At least 5000 events were evaluated with a fluorescence-activated cell-
sorting Flow-Cytometer (FACSCaliburTM) and Cell-Quest-data-acquisition and analysis-
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software (Becton Dickson, Heidelberg, Germany). Isotype controls were conducted according 
to manufacturer’s instructions. 
For the analysis and quantification of T, iNKT, NK and CIK cells/ subtypes were quantified in 
the total cell-fraction (e.g: CD3+ cells) or in the subpopulations (e.g: 6B11+CD3+). According 
to their expression profile we quantified proportions of immune reactive cells as given in Table 
7-10: T cells: CD3+, CD8+, CD4+, Vα24+, CD1d+ T-cells, Tnaive, Tnon-naïve, Tcm or   Teff-em.9,10,13,14 
CIK cells: CD3+CD56+ or CD3+CD161+ cells5. NK cells: CD3-CD56+ or CD3-CD161+ cells.5,13 
(6B11+) iNKT cells: 6B11+CD3+, 6B11+CD161+, 6B11+Vα24+, 6B11+CD4+, 6B11+CD8+, 
6B11+CD1d+, 6B11+CD45RO+ or 6B11+CD45RO- iNKT cells11,13.  
 
Table 7: Subtypes of T cells as evaluated by flow cytometry 
1total proportions of cell-subsets in uncultured MNC, WB or in MLC (after culture with T cells and IL-2) 
 
 
Table 8: Subtypes of CIK cells as evaluated by flow cytometry 
 
 
Names of subgroups referred to Surface marker Abbreviation Explanatory note/premise
CD3
+
 pan-T-cells MNC(WB) or MLC
1
CD3
+
CD3
+
/MNC(WB) or MLC
CD4
+
-coexpressing T-cells MNC(WB) or MLC CD3
+
CD4
+ 
CD4
+
/MNC(WB) or MLC CD4
+
 T-cells
CD4
+
-coexpressing T-cells CD3
+
CD3
+
CD4
+ 
CD4
+
/CD3
+
CD4
+
 T-cells
CD8
+
-coexpressing T-cells MNC(WB) or MLC CD3
+
CD8
+
CD8
+
/MNC(WB) or MLC CD8
+
 T-cells
CD8
+
-coexpressing T-cells CD3
+
CD3
+
CD8
+
CD8
+
/CD3
+
CD8
+
 T-cells
naive T-cells MNC(WB) or MLC CD3
+
CD45RO
-
Tnaive/MNC(WB) or MLC Unprimed T-cells
naive T-cells CD3
+
CD3
+
CD45RO
- 
Tnaive/CD3
+
Unprimed T-cells
non-naive T-cells MNC(WB) or MLC CD3
+
CD45RO
+
Tnon-naive/MNC(WB) or MLC Memory + effector T-cells
non-naive T-cells CD3
+
CD3
+
CD45RO
+
Tnon-naive/CD3
+
Memory + effector T-cells
central (memory) T-cells MNC(WB) or MLC CD3
+
CCR7
+
CD45RO
+
Tcm/MNC(WB) or MLC Long-term immunity
central (memory) T-cells CD3
+
CD3
+
CCR7
+
CD45RO
+
Tcm/CD3
+
Long-term immunity
effector (memory) T-cells MNC(WB) or MLC CD3
+
CCR7
-
CD45RO
+
Tems-Teffs/MNC(WB) or MLC
effector (memory) T-cells CD3
+
CD3
+
CCR7
-
CD45RO
+
Tems-Teffs/CD3
+
proliferating T-cells MNC(WB) or MLC CD3
+
CD69
+
Tprol/MNC(WB) or MLC proliferating T-cells 
proliferating T-cells CD3
+
CD3
+
CD69
+
Tprol/CD3
+
proliferating T-cells 
Viable T-cells MNC(WB) or MLC CD3
+
7AAD
-
Tvia/MNC(WB) or MLC
Viable T-cells CD3
+
CD3
+
7AAD
-
Tvia/CD3
+
TCRVα24
+
-coexpressing T-cells MNC(WB) or MLC CD3
+
Vα24
+
Vα24
+
/MNC(WB) or MLC Vα24 segment joined with Jα18 
TCRVα24
+
-coexpressing T-cells CD3
+
CD3
+
Vα24
+
Vα24
+
/CD3
+
Vα24 segment joined with Jα18 
CD1d
+
-coexpressing T-cells MNC(WB) or MLC CD3
+
CD1d
+
CD1d
+
/MNC(WB) or MLC CD1d
+
 is a MHC class I-like molecule
CD1d
+
-coexpressing T-cells CD3
+
CD3
+
CD1d
+
CD1d
+
/CD3
+
CD1d
+
 is a MHC class I-like molecule
Names of subgroups referred to Surface marker Abbreviation Explanatory note/premise
CD3
+
CD56
+
 CIK-cells MNC(WB) or MLC CD3
+
CD56
+
CD3
+
CD56
+
/MNC(WB) or MLC Cells expressing T-cell (CD3) and 
CD3
+
CD161
+ 
CIK-cells MNC(WB) or MLC CD3
+
CD161
+
CD3
+
CD161
+
/MNC(WB) or MLC NK-cell (CD56,CD161) markers
CD3
+
 CD161
+
 CIK-cells CD3
+
CD3
+
CD161
+
CD3
+
CD161
+
/CD3
+
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Table 9: Subtypes of NK cells as evaluated by flow cytometry 
 
 
Table 10: Subtypes of iNKT cells as evaluated by flow cytometry 
 
 
Exemplarily, dot plots iNKT, NK and CIK cells (Figure 1+2) and the gating strategy of iNKT 
cells and subsets are given (Figure 3).  
 
Figure 1: Dot plots of NK and CIK cells in healthy- (left side) and AML-MNC (right side)  
 
 
 
 
 
 
 
 
 
  
 
 
Legend: Dot plots of various frequencies of NK (CD3-CD56+) and CIK cells (CD3+CD56+) in 
healthy or AML MNC are given.  
 
Names of subgroups referred to Surface marker Abbreviation Explanatory note/premise
CD3
-
CD56
+ 
NK-cells MNC(WB) or MLC CD3
-
CD56
+
CD3
-
CD56
+
/MNC(WB) or MLC Cells expressing NK markers (CD56,
CD3
-
CD161
+
 NK-cells MNC(WB) or MLC CD3
-
CD161
+
CD3
-
CD161
+
/MNC(WB) or MLC CD161), but not expressing T-cell 
CD3
-
CD161
+ 
NK-cells CD161
+
CD3
-
CD161
+
CD3
-
CD161
+
/CD161
+ markers (CD3)
Names of subgroups referred to Surface marker Abbreviation Explanatory note/premise
6B11
+
(PE) iNKT-cells MNC(WB) or MLC 6B11
+
6B11
+
(PE)/MNC(WB) or MLC 6B11 recognizes the invariant CDR3 
6B11
+
(FITC)
 
iNKT-cells MNC(WB) or MLC 6B11
+
6B11
+
(FITC)/MNC(WB) or MLC loop of the TCR α-chain of iNKT cells
CD3
+
 coexpressing 6B11
+
 iNKT-cells MNC(WB) or MLC 6B11
+
CD3
+
6B11
+
CD3
+
/MNC(WB) or MLC 6B11
+
CD3
+ 
iNKT-cells
CD3
+
 coexpressing 6B11
+
 iNKT-cells CD3
+
6B11
+
CD3
+
6B11
+
CD3
+
/CD3
+
6B11
+
CD3
+ 
iNKT-cells
CD4
+
 coexpressing 6B11
+
 iNKT-cells MNC(WB) or MLC 6B11
+
CD4
+
6B11
+
CD4
+
/MNC(WB) or MLC 6B11
+
CD4
+
 iNKT-cells
CD4
+
 coexpressing 6B11
+
 iNKT-cells CD4
+
6B11
+
CD4
+
6B11
+
CD4+/CD4+ 6B11
+
CD4
+
 iNKT-cells
CD8
+
 coexpressing 6B11
+
 iNKT-cells MNC(WB) or MLC 6B11
+
CD8
+
6B11
+
CD8
+
/MNC(WB) or MLC 6B11
+
CD8
+
 iNKT-cells
CD8
+
 coexpressing 6B11
+
 iNKT-cells CD8
+
6B11
+
CD8
+
6B11
+
CD8
+
/CD8
+
6B11
+
CD8
+
 iNKT-cells
CD1d
+
 coexpressing 6B11
+
 iNKT-cells MNC(WB) or MLC 6B11
+
CD1d
+ 
6B11
+
CD1d
+
/MNC(WB) or MLC 6B11
+
CD1d
+
 iNKT-cells
CD1d
+
 coexpressing 6B11
+
 iNKT-cells 6B11
+
6B11
+
CD1d
+ 
6B11
+
CD1d
+
/6B11
+
6B11
+
CD1d
+
 iNKT-cells
CD161
+
 coexpressing 6B11
+
 iNKT-cells MNC(WB) or MLC 6B11
+
CD161
+ 
6B11
+
CD161
+
/MNC(WB) or MLC 6B11
+
CD161
+
 iNKT-cells
CD161
+
 coexpressing 6B11
+
 iNKT-cells 6B11
+
6B11
+
CD161
+
6B11
+
CD161
+
/6B11
+
6B11
+
CD161
+
 iNKT-cells
CD161
+
 coexpressing 6B11
+
 iNKT-cells CD161
+
6B11
+
CD161
+ 
6B11
+
CD161
+
/CD161
+
6B11
+
CD161
+
 iNKT-cells
TCRVα24
+
 coexpressing 6B11
+
 iNKT-cells MNC(WB) or MLC 6B11
+
Vα24
+
6B11
+
Vα24
+
/MNC(WB) or MLC 6B11
+
Vα24
+
 iNKT-cells
TCRVα24
+
 coexpressing 6B11
+
 iNKT-cells 6B11
+
6B11
+
Vα24
+ 
6B11
+
Vα24
+
/6B11
+
6B11
+
Vα24
+
 iNKT-cells
CD45RO
+
 coexpressing 6B11
+
 iNKT-cells MNC(WB) or MLC 6B11
+
CD45RO
+
6B11
+
CD45RO
+
/MNC(WB) or MLC 6B11
+
CD45RO
+
 iNKT-cells
CD45RO
+
 coexpressing 6B11
+
 iNKT-cells 6B11
+
6B11
+
CD45RO
+
6B11
+
CD45RO
+
/6B11
+
6B11
+
CD45RO
+
 iNKT-cells
CD45RO
-
6B11
+
 iNKT-cells MNC(WB) or MLC 6B11
+
CD45RO
- 
6B11
+
CD45RO
-
/MNC(WB) or MLC 6B11
+
CD45RO
-
 iNKT-cells
CD45RO
-
6B11
+
 iNKT-cells 6B11
+
6B11
+
CD45RO
-
6B11
+
CD45RO
-
/6B11
+
6B11
+
CD45RO
-
 iNKT-cells
4.92% 8.56% 2.80% 4.04% 
 
8.56% 4.92  2.80  
  
24 
 
Figure 2: Dot plots of iNKT cells in healthy- (left side) and AML-MNC (right side) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: Dot plots of various frequencies of iNKT cells (6B11+CD3+ and 6B11+CD3-) in 
healthy or AML MNC are given.  
 
Figure 3: Gating strategy of iNKT cells and subsets in AML-MNC 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Legend: Gating strategy of 6B11+ iNKT cells and characterization of corresponding dot plots 
of iNKT cells subsets (6B11+CD3+CD161+ and 6B11+CD3-CD161+) in healthy and AML MNC 
are given. R1 = Gate surrounding all 6B11+cells in the AML-MNC-fraction. 
 
For the analysis and quantification of DC/ DCleu subtypes in the total- or in subtype-cell-
fractions after DC-culture in the MNC or WB fraction (DCleu/ cells) we used a refined gating 
strategy6,8: Subgroup analyses were conducted only in cases with ≥10% DC. DCleu were 
quantified in the total fraction (DCleu/ cells) in the DC-fraction (DCleu/ DC) or in the blast 
fraction, to quantify the amount of blasts converted to DCleu (DCleu/ bla), mature DC (co-
expressing the migration marker CCR7) and viable DC (negative for 7AAD) were quantified 
in the DC fraction after culture (DCmig/ DC; DCvia/ DC, Table 11) 
6,8. For this purpose, cells 
were stained with patient-specific ‘blast’-staining antibodies (e.g. CD15, CD34, CD65 and 
CD117) according to diagnostic reports before culture in combination with ‘DC’-staining 
 
2.45% 4.96% 1.16% 0.93% 
R
1 
4.96% 2.45% 
R1 
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antibodies (e.g. CD80, CD83, CD86, CD206 and CD209), which were not expressed before 
culture.  
Table 11: Subtypes of DC as evaluated by flow cytometry 
 
 
To analyze whether 6B11 or CD161 is aberrantly expressed on blasts or not (Table 12), we 
evaluated eight different leukemic cell lines (HL-60, OCI-AML2, THP-1, Mono-Mac-6, 
MOLM-13, RAMOS, RAJI, JURKAT). 
 
Table 12: Subtypes of blasts as evaluated by flow cytometry 
1cells expressing blast markers: patients’ individually selected blast-markers with the highest expression (see Table 1-5: blast phenotype) 
 
4.6 Cytotoxicity (fluorolysis) assay 
 
To analyze the blast lytic activity of T cell-enriched immune reactive cells after MLC with 
‘cocktails’-pretreated or not pretreated stimulator cell suspensions from MNC or WB a 
fluorolysis assay was performed.19 Therefore, effector cells (E) were co-cultured 1:1 with 
thawed blast-containing target cells (T) for 3h and 24h at 37°C, with 21% O2 and 5% CO2. As 
a control effector- and target-cells were cultured for the same time separately and mingled on 
ice shortly before the flow cytometric analyses were carried out. Before culture, target-cells 
were stained for 15 minutes with FITC-, PE- or APC-conjugated blast-, monocyte- or T cell-
specific target cell antibodies. To evaluate viable cells and the lytic activity of effector cells, 
the cultures were harvested after 3h and 24h and resuspended in PBS containing 7AAD (Becton 
Dickson, Heidelberg, Germany) and a defined number of Fluorospheres beads (Beckman 
Names of subgroups referred to Surface marker Abbreviation Explanatory note/premise
DC cells DC
+
 (CD80, CD86, CD206) DC/cells ≥ 10 % DC in cells
leukemia derived DC cells DC
+
bla
+
DCleu/cells ≥ 5% DCleu in cells, ≥ 10% DC, ≥ 10% bla
blasts converted to DCleu in blast fraction bla
+ 
DC
+
bla
+
DCleu/bla
+
≥ 5% DCleu in cells, ≥ 10% DC, ≥ 10% bla
DCleu in DC fraction DC DC
+
bla
+
DCleu/DC ≥ 5% DCleu in cells, ≥ 10% DC, ≥ 10% bla
migratory  mature DC in DC fraction cells DC
+
CCR7
+
DCmig/DC ≥ 10% DC in cells
viable DC in DC-fraction cells DC
+
7AAD
-
DCvia/DC ≥  10% DC in cells
Names of subgroups referred to Surface marker Abbreviation
Blast cells
 1
MNC(WB) or MLC bla
+ 
bla
+ 
blasts coexpressing CD161 MNC(WB) or MLC bla
+
CD161
+
bla
+
CD161
+
/MNC(WB) or MLC
blasts coexpressing CD161 bla
+ 
bla
+
CD161
+
bla
+
CD161
+
/bla
+
blasts coexpressing 6B11 MNC(WB) or MLC bla
+
6B11
+
bla
+
6B11
+
/MNC(WB) or MLC
blasts coexpressing 6B11 bla
+ 
bla
+
6B11
+
bla
+
6B11
+
/bla
+
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Coulter, Krefeld, Germany). For analyses, a refined gating was used. 8 Therefore, viable target 
cells were gated in a FSC/ 7AAD- gate. With a FACS CaliburTM Flow Cytometer and a CELL-
Quest software (Becton Dickson, Heidelberg, Germany) cells were analyzed. The lytic activity 
was calculated and defined as the difference in the percentage of viable target blasts before and 
after the effector cell contact. 
 
4.7 Statistical Methods 
 
Data were presented as mean +/- standard-deviation. Statistic comparisons for two groups were 
performed using the t-test and Mann-Whitney-Wilcoxon test. The statistical analysis was done 
with Microsoft Excel 2010 or 2013 ® (Microsoft, Redmond, Washington, USA). Differences 
were considered as ‘not significant’ (n.s.) with p values >0.1, as ‘borderline significant’ 
(significant*) with p values between 0.1 and 0.05, as ‘significant’ (significant**) with p values 
between 0.05 and 0.005 and as ‘highly significant’ (significant***) with p values <0.005. 
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 Results 
 
5.1 Prolog 
 
During the development of acute and chronic leukemia B, T lymphocytes and monocytes are 
displaced by increasing blast cell-populations. In our samples between 8 and 99% of blast cells 
and varying proportions of the remaining hematopoietic cells were detectable. Details of the 
cellular composition of AML, ALL and CLL samples are shown in Table 13+14. Samples with 
blasts, that aberrantly expressed CD3, CD4, CD8, CD14 or CD19, were excluded from 
quantification-analyses for the respective lineage-markers.  
In our first approach (Table 13), we compared frequencies and compositions of iNKT, NK and 
CIK cells as well as T cell subtypes in (unstimulated) MNC from healthy donors with AML, 
ALL and CLL patients and correlated findings with prognosis of these patients. Moreover, we 
studied potential (aberrant) coexpressions of iNKT markers on leukemic cell lines. 
 
Table 13: Uncultured AML, ALL, CLL and healthy samples 
 
1only quantified in B-linear ALL; 2only quantified in T-linear ALL 
Cell type  Ø % (MNC)  range % (MNC)
Blasts (myeloid blasts) 69 18 - 99
AML T-cells (CD3
+
) 6  1 - 33
B-cells (CD19
+
) 6  1 - 33
Monocytes (CD14
+
) 8 2 - 18
Blasts (B- or T-linear blasts) 71 17 - 99
ALL T-cells
1 
(CD3
+
) 14 5 - 33
B-cells
2 
(CD19
+
) 8 3 - 11
Monocytes (CD14
+
) 5 1 - 29
Blasts (B-linear blasts) 85 32 - 98
CLL T-cells (CD3
+
) 11 1 - 60
Monocytes (CD14
+
) 4 1 - 25
T-cells (CD3
+
) 41 24 - 64
Healthy B-cells (CD19
+
) 24 14 - 32
Monocytes (CD14
+
) 3 1 - 6
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In our second approach (Table 14), we analysed proportions of AML blasts and immune 
reactive cells (with a special focus on iNKT, NK and CIK cells) and their expression profiles 
after MLC. 
 
Table 14: AML and healthy samples used for culture experiments 
 
 
The 6B11- antibody, targeting the invariant CDR3 loop of the V24J18 TCR, is regarded as 
a specific antibody to detect iNKT cells. In our experiments, we used two different antibodies: 
6B11 (clone 6B11) labeled with PE (6B11-PE, delivered by BD) and 6B11 (clone 6B11) 
labeled with FITC (6B11-FITC, delivered by Biozol). First comparative analyses with these 
markers in MNC from AML, ALL, CLL patients revealed significantly* higher proportions of 
iNKT cells detected with the 6B11-FITC compared to 6B11-PE (AML: 1.52%1.74% vs 
0.75%1.10%, p<0.0652; ALL: 1.24%1.52% vs 0.74%0.64%, p<0.103; CLL: 
0.92%0.87% vs 0.78%0.47%, p<0.299). However, proportions of iNKT cells detected with 
6B11-FITC were significantly** lower in healthy samples compared to leukemic samples 
(AML: 0.40%0.26% vs 1.52%1.74%, p<0.01073; ALL: 0.40%0.26% vs 1.24%1.52%, 
p<0.01622; CLL: 0.40%0.26% vs 0.92%0.87%, p<0.02267), while iNKT cells detected with 
6B11-PE were significantly* higher in healthy samples compared to leukemic samples (AML: 
2.47%3.12% vs 0.75%%1.10%, p<0.081; ALL: 2.47%3.12% vs 0.74%0.65%, p<0.083; 
CLL:  2.47%3.12% vs 0.78%0.47%, p<0.0827). We decided for better comparibility to 
present only data obtained with 6B11-PE. 
We evaluated eight different leukemic cell lines (HL-60, OCI-AML2, THP-1, Mono-Mac-6, 
MOLM-13, RAMOS, RAJI, JURKAT) to analyze if 6B11 or CD161 is aberrantly expressed 
Cell type  Ø % (WB/MNC)  range % (WB/MNC) 
Blasts 28 / 17 8-60 / 15-18
AML T-cells (CD3
+
) 21 / 11 2-54 / 5-17
B-cells (CD19
+
) 1 / 5 0-2 / 2-8
Monocytes (CD14
+
) 11 / 7 0-32 / 3-13
T-cells (CD3
+
) 18 / 35 14-21 / 9-48
Healthy B-cells (CD19
+
) 3 / 7 1-4 / 3-12
Monocytes (CD14
+
) 6 / 7 5-8 / 3-12
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on blasts. We could demonstrate that neither CD161 nor 6B11 were (aberrantly) expressed on 
blasts of leukemic myeloid and B lineage cell lines with a mean coexpression on blasts of 
2.59%0.02% or 2.67%0.03%. However, 8.38% 6B11+bla+ and 10.03% CD161+bla+ cells 
were found in the T-linear Jurkat cell line. Moreover, we could demonstrate that neither CD161 
nor 6B11 were aberrantly expressed on leukemic blasts obtained from patients with AML, ALL 
or CLL. On average, coexpression of CD161 and 6B11 on blasts was: AML: 0.23%  0.01% 
or 0.35% 0.01%; ALL: 0.55% 0.01% or 0.66% 0.01%; CLL: 0.17% 0.00% or 1.60% 
0.01%. 
Therefore, analysing iNKT cells with 6B11-PE and NK/ CIK cells with CD161 represent 
specific results as 6B11 and CD161 antibodies do not show unspecific bindings on blasts, 
although combinations of (fluorochrome)-labeled antibodies have to be tested thoroughly. 
 
5.2 Monoclonal antibodies and their combinations for iNKT, NK and CIK cell/ subtype 
analyses  
 
For iNKT cell detection in healthy and AML, ALL and CLL samples, we used moAb 6B11 
alone or in combination with CD3, CD161, V24, CD1d, CD45RO, CD4 and CD8. We defined 
iNKT cells detected with 6B11 in combination with T cell markers (CD3, V24, CD1d, 
CD45RO, CD4 and CD8) as ‘T cell-like’ iNKT cells and iNKT cells detected with 6B11 in 
combination with NK-cell-markers (CD161) as ‘NK cell-like’ iNKT cells. The frequencies of 
iNKT cells detected with 6B11 alone were similar in AML, ALL and CLL patients 
(0.75%1.10% vs 0.74%0.65% vs 0.78%0.47%). Frequencies of iNKT cells detected with 
6B11 in combination with CD3 (6B11+CD3+/MNC) were slightly lower in AML, ALL and 
CLL patients (0.58%1.15% vs 0.61%0.42% vs 0.46%0.47%), but the percentages were 
comparable to results with 6B11 in combination with CD1d (6B11+CD1d+/MNC, 
0.66%1.16% vs 0.66%0.96% vs 0.48%0.64%). Proportions of 6B11+CD161+/MNC iNKT 
cells were even smaller in AML, ALL and CLL patients (0.14%0.25% vs 0.18%0.16% vs 
0.22%0.26%), while 6B11+ V24 +/MNC could only detect very few frequencies of iNKT 
cells (0.09%0.10% vs 0.08%0.18% vs 0.03%0.03%). We could show higher frequencies of 
6B11+CD4+ MNC vs 6B11+ CD8+/MNC iNKT cells detected in AML, ALL and CLL patients 
(CD4+ iNKT cells: 0.18%0.20% vs 0.32%0.33% vs 0.25%0.12%; CD8+ iNKT cells:  
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0%
2%
4%
AML
n=23
Healthy
n=9
CD3+CD56+/MNC
p<0.0021
0%
2%
4%
AML
n=23
Healthy
n=9
CD3+CD161+/MNC
p<0.00015
0.03%0.04% vs 0.07%0.09% vs 0.06%0.05%). Moreover, we could show that the majority 
of 6B11+iNKT cells express CD45RO in AML, ALL and CLL patients (88.58%14,43% vs 
79.75%30.00% vs 64.58%29.53%).  
In conclusion, frequencies of iNKT cells and their subsets can be detected with 6B11 alone 
(PE-labeled clone preferred) or in combination with CD3, CD161, CD1d or V24. The 
combination of 6B11 with CD4, CD8 and CD45RO can be used for further subset-analyses of 
iNKT cells.  
 
5.3 Numbers and compositions of iNKT, NK and CIK cells from AML patients 
compared to healthy probands and their correlations with the prognosis  
 
5.3.1 AML patients show significantly lower proportions of iNKT, NK and CIK cells in MNC 
compared to healthy MNC 
 
We found significantly*** lower frequencies of CD3+CD56+ CIK cells in MNC of AML patients 
compared to healthy MNC (0.46%0.62% vs 2.74%1.64%, p<0.0021) and significantly*** 
lower percentages of CD3+CD161+ CIK cells (0.30%0.40% vs 3.25%1.02%, p<0.000152, 
Figure 4).  
 
Figure 4: CIK cell frequencies in healthy- versus AML-MNC 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of CIK cells and their subsets (CD3+CD56+/MNC and 
CD3+CD161+/MNC) in healthy vs AML MNC are given. 
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p<0.00064
0%
5%
10%
15%
AML
n=23
Healthy
n=9
CD3-CD161+/MNC
p<0.0142
Additionally, we could show significantly*** lower proportions of CD3-CD56+ NK cells 
(1.68%1.97% vs 9.33%4.06%, p<0.00064) and significantly** lower proportions of CD3-
CD161+ NK cells in MNC of AML patients compared to healthy MNC (1.01%1.26% vs 
2.44%1.20%, p<0.0142, Figure 5).  
 
Figure 5: NK cell frequencies in healthy- versus AML-MNC 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of NK cells and their subsets (CD3-CD56+/MNC and CD3-CD161+/MNC) 
in healthy vs AML MNC are given. 
 
We could demonstrate significantly* lower percentages of 6B11+ iNKT cells (0.75%1.10% vs 
2.47%3.12%, p<0.081) and (n.s.) lower proportions of 6B11+CD3+ and 6B11+CD161+iNKT-
cells in MNC of AML patients compared to healthy MNC (Figure 6).  
 
Figure 6: iNKT cell frequencies in healthy- versus AML-MNC 
 
 
 
 
 
 
 
 
 
 
  
Legend: Frequencies of iNKT cells and their subsets (6B11+/MNC, 6B11+CD3+/MNC and 
6B11+CD161+/MNC) in healthy vs AML MNC are given. 
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p<0.00152
Moreover, 6B11+CD8+ and 6B11+V24+ iNKT cells were found in lower proportions in MNC 
from AML patients vs healthy MNC (data not shown (d.n.s.)).  
In summary frequencies of 6B11+/ 6B11+CD3+/ 6B11+CD161+/ 6B11+CD8+/ 6B11+Vα24+ 
iNKT, CD3-CD56+/ CD3-CD161+ NK and CD3+CD56+/ CD3+CD161+ CIK cells/ subsets were 
(significantly) lower in MNC from AML patients than in healthy MNC. 
 
5.3.2 Significantly higher proportions of T and NK cells express 6B11 in AML patients 
compared to healthy probands 
 
We found significantly*** increased proportions of CD3+ T cells expressing 6B11 in AML 
patients compared to healthy controls (14.03%14.66% vs 2.69%2.17%, p<0.00111, Figure 
7).  
 
Figure 7: iNKT cell frequencies in the NK and T cell fraction in healthy- versus AML-MNC 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of iNKT cell subsets in the T cell fraction (6B11+CD3+/CD3+) and in the 
NK cell fraction (6B11+CD161+/CD161+) in healthy vs AML MNC are given. 
 
Moreover, we found significantly** higher frequencies of CD4+ (8.36%15.22% vs 
0.31%0.38%, p<0.0123) and CD161+ cells expressing 6B11 (17.19%15.36% vs 
4.62%5.97%, p<0.0152, Figure 7) and significantly* increased frequencies of CD8+ cells 
expressing 6B11 in MNC from AML patients vs healthy controls (1.89%3.55% vs 
0.59%1.12%, p<0.0723). We did not find significant differences of CD3+CD161+ CIK cells 
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in the CD3+ T cell fraction of AML patients compared to CD3+CD161+ CIK cells in the healthy 
T cell fraction (d.n.s.). 
In summary, a shift to higher proportions of (CD3+/CD4+/CD8+) T cells and (CD161+) NK cells 
co-expressing 6B11 was found in AML patients compared to healthy samples. No differences 
of CD3+CD161+ CIK cells in the CD3+ T cell fraction were observed.  
 
5.3.3 AML patients with prognostically favorable subgroups are characterized by higher 
proportions of iNKT, NK and CIK cells 
 
AML patients who achieved CR after induction chemotherapy were characterized by 
significantly** higher frequencies of CD3+CD56+ CIK cells in MNC-fractions than AML 
patients with no complete remission (NCR; 0.4%  0.33% vs 0.05%  0.05%, p<0.0094, Figure 
8, left side), whereas proportions of NK or iNKT cells were not different in MNC fractions of 
patients who achieved vs not achieved a CR (d.n.s).  
 
Figure 8: Prognostic relevance of CIK and iNKT cells for AML patients - response to 
chemotherapy (CR vs NCR, left side), allocation to favorable vs adverse risk score (NCCN, 
middle row), allocation to age groups (<60 vs 60 years, right side) 
 
 
 
 
 
 
 
 
  
Legend: Relevance of CIK and iNKT cells for prognosis of AML patients. Frequencies of CIK 
cells (CD3+CD56+/MNC) in patients with CR vs NCR after induction chemotherapy and iNKT 
cells (6B11+/MNC) in patients with favorable vs adverse risk score (NCCN) and <60 vs >60 
years are given.  
 
AML patients with favorable vs adverse NCCN risk score presented with (n.s) higher values of 
6B11+ iNKT cells in the MNC-fraction (0.64% 0.11% vs 0.56% 0.09%; Figure 8, middle 
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row). Comparable results were found for 6B11+Va24+- and 6B11+CD161+ iNKT cel 
proportions in the MNC-fraction of AML patients with favorable vs adverse NCCN risk score 
(d.n.s). 
AML patients younger than 60 years presented with (n.s) higher frequencies of 6B11+iNKT 
cells in the MNC-fraction compared to AML patients older than 60 years (0.89%1.35% vs 
0.53%0.40%, Figure 8, right side). Comparable results were found for 6B11+CD3+ and 
6B11+CD161+ iNKT cell proportions in the MNC-fraction of AML patients younger than 60 vs 
older than 60 years (d.n.s). No differences were found for proportions of NK or CIK cells in 
the groups compared (d.n.s). 
AML patients with primary vs secondary AML presented with (n.s) higher frequencies of 
6B11+ and 6B11+CD3+ iNKT cells in the MNC-fraction (0.78%1.21% vs 0.62%0.46%; 
0.66%1.29% vs 0.32%0.23%). No differences were found for proportions of NK or CIK 
cells in the groups compared (d.n.s). 
AML patients without extramedullary foci (n=20) compared to those with extramedullary foci 
(n=3) presented with significantly*** increased proportions of CD3+CD56+CIK cells in the 
MNC-fraction (0.53% 0.63% vs 0.00% 0%; p<0.0023, Figure 9 left side).  
 
Figure 9: Prognostic relevance of CIK, NK and iNKT cells for AML patients - extramedullary 
versus no extramedullary foci  
 
 
 
 
 
 
 
 
  
Legend: Relevance of CIK, NK and iNKT cells for prognosis of AML patients. Frequencies of 
CIK (CD3+CD56+/MNC), NK (CD3-CD56+/MNC) and iNKT cells (6B11+/MNC) in patients 
with extramedullary vs no extramedullary foci are given. 
 
Moreover, the percentages of CD3-CD56+ NK cells were significantly*** higher in cases without 
compared to patients with extramedullary foci (1.97%  0.21% vs 0.08%  0.04%; p<0.0017, 
p<0.0023 
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Figure 9 middle row). Furthermore, we found (n.s) higher frequencies of 6B11+ iNKT cells in 
the MNC fraction of AML patients without vs with extramedullary foci (0.81% 1.16% vs 
0.37%0.24%, Figure 9 right side). Comparable results were found for 6B11+CD3+ and 
6B11+CD161+iNKT cell proportions in the MNC-fraction in the groups compared (d.n.s). 
AML patients who stayed in stable CR vs no stable CR (NCR) showed (n.s) higher frequencies 
of CD3+CD161+ CIK cells and CD3-CD161+NK cells in the MNC-fraction (0.47%0.58% vs 
0.16%0.08%; 1.21%1.73% vs 0.90%072%, Figure 10 left side and middle row).  
 
Figure 10: Prognostic relevance of CIK, NK and iNKT cells for AML patients - stable CR 
(yes or no) 
 
 
 
 
 
 
 
 
  
Legend: Relevance of CIK, NK and iNKT cells for prognosis of AML patients. Frequencies of 
CIK (CD3+CD56+/MNC), NK (CD3-CD56+/MNC) and iNKT cells (6B11+/MNC) in patients 
with stable vs no stable disease are given. 
 
Moreover, we found (n.s) higher percentages of 6B11+iNKT cells in the MNC-fraction of AML 
patients who stayed in stable CR vs NCR (1.04%1.63% vs 0.37%0.10%, Figure 10 right 
side). Comparable results were found for 6B11+CD3+ and 6B11+CD161+ iNKT cell proportions 
in the MNC fraction in the groups compared (d.n.s). 
In summary, in AML patients (significantly) higher proportions of 6B11+iNKT cells correlated 
with favorable NCCN risk score, younger age, primary AML, no extramedullary foci and stable 
CR. Similar correlations were found for 6B11+CD3+/ 6B11+CD161+ and 6B11+Vα24+iNKT 
subsets. High frequencies of CD3-CD56 NK cells and CD3+CD56+ CIK cells correlated 
significantly with no extramedullary foci. Moreover, higher proportions of CD3-CD161+NK 
cells and CD3+CD161+CIK cells correlated with stable CR in AML patients and CD3+CD56+ 
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CIK cells correlated with the achievement of CR after induction chemotherapy in AML 
patients. 
 
5.4 Numbers and compositions of iNKT, NK and CIK cells from ALL patients 
compared to healthy probands and their correlations with the prognosis  
 
5.4.1 ALL patients show significantly lower proportions of iNKT, NK and CIK cells in MNC 
compared to healthy MNC 
 
We found significantly** lower frequencies of CD3+CD56+CIK cells in MNC of ALL patients 
compared to healthy MNC (1.36%±1.63% vs 2.74%±1.64%, p<0.0395) and significantly*** 
lower percentages of CD3+CD161+CIK cells (0.94%±1.45% vs 3.25%±1.02%, p<0.00039, 
Figure 11).  
 
Figure 11: CIK cell frequencies in healthy- versus ALL-MNC 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of CIK cells and their subsets (CD3+CD56+/MNC and 
CD3+CD161+/MNC) in healthy vs ALL MNC are given. 
 
Moreover, we found significantly*** lower proportions of CD3-CD56+NK cells (2.68%±2.35% 
vs 9.33%±4.06% p<0.00163) and significantly*** lower proportions of CD3-CD161+NK cells 
in MNC from ALL patients vs healthy MNC (0.52%±0.92% vs 2.44%±1.20%, p<0.00344, 
Figure 12).  
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Figure 12: NK cell frequencies in healthy- versus ALL-MNC 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of NK cells and their subsets (CD3-CD56+/MNC and CD3-CD161+/MNC) 
in healthy vs ALL MNC are given. 
 
We could show significantly* lower frequencies of 6B11+iNKT cells in MNC from ALL 
patients vs healthy MNC (0.74%±0.65% vs 2.47%±3.12%, p<0.083, Figure 13).  
 
Figure 13: iNKT cell frequencies in healthy- versus ALL-MNC 
 
 
 
 
 
 
 
 
 
 
  
Legend: Frequencies of iNKT cells and their subsets (6B11+/MNC, 6B11+CD3+/MNC and 
6B11+CD161+/MNC) in healthy vs ALL MNC are given. 
 
Moreover, 6B11+CD3+/ 6B11+CD8+/ 6B11+CD161+ and 6B11+V24+iNKT cells were found 
in (n.s) lower proportions in MNC from ALL patients vs healthy MNC (d.n.s).  
In summary frequencies of 6B11+/ 6B11+CD3+/ 6B11+CD161+/ 6B11+CD8+/ 6B11+Vα24+ 
iNKT, CD3-CD56+/ CD3-CD161+ NK and CD3+CD56+/ CD3+CD161+ CIK cells/ subsets were 
(significantly) lower in ALL-MNC than in healthy MNC. 
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5.4.2 Significantly higher proportions of T and NK cells express 6B11 in ALL patients 
compared to healthy probands 
 
We found significantly* lower percentages of CD3+CD161+ CIK cells in the CD3+ T cell 
fraction of ALL-patients compared to CD3+CD161+CIK cells in the healthy CD3+ T cell 
fraction (5.25%±7.17% vs 8.92%±2.82%, p<0.053), but significantly** higher proportions of 
CD3+ T cells expressing 6B11 in ALL patients compared to healthy controls (6.03%±5.25% vs 
2.69%±2.17%, p<0.0102, Figure 14).  
Furthermore, we found significantly** higher frequencies of CD4+ (7.27%±11.04% vs 
0.31%±0.38%, p<0.00745) and CD161+ cells expressing 6B11 (15.63%±16.46% vs 
4.62%±5.97%, p<0.0057, Figure 14) and significantly* higher percentages of CD8+cells 
expressing 6B11 in ALL patients vs healthy controls (1.28%±1.44% vs 0.59%±1.12%, 
p<0.081). 
 
Figure 14: iNKT cell frequencies in the NK and T cell fraction in healthy- versus ALL-MNC  
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of iNKT cell subsets in the T cell fraction (6B11+CD3+/CD3+) and in the 
NK cell fraction (6B11+CD161+/CD161+) in healthy vs ALL MNC are given. 
 
In summary, a shift to higher proportions of (CD3+/CD4+/CD8+) T cells and (CD161+) NK cells 
coexpressing 6B11 was found in ALL patients compared to healthy samples. However, unlike 
in AML -patients, lower frequencies of CD3+CD161+CIK cells were found in the CD3+T cell 
fraction of ALL patients vs in the healthy CD3+ T cell fraction.  
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5.4.3 Adult ALL patients with prognostically favorable subgroups are characterized by 
higher proportions of iNKT and NK cells 
 
The ALL patients’ cohort included children and adults. Since only one child relapsed only adult 
ALL patients (treated with GMALL-therapy) were included in prognostic analyses. 
Adult ALL patients who achieved a CR after GMALL-induction-chemotherapy were 
characterized by (n.s) higher frequencies of CD3-CD161+NK cells in MNC-fractions than ALL 
patients without achieved CR (1.09%  1.48% vs 0.18%  0.11%, d.n.s). Moreover, we found 
(n.s) higher percentages of 6B11+, 6B11+CD3+ and 6B11+Vα24+ iNKT cells in the MNC-
fraction of ALL patients who achieved CR vs NCR (0.95%1.02% vs 0.65%0.37%; 
0.61%0.34% vs 0.58%0.26%; 0.16%0.30% vs 0.03%0.05%, d.n.s). No differences were 
found for CIK cells. 
Adult ALL patients without extramedullary foci compared to those with extramedullary foci 
presented with (n.s) higher proportions of 6B11+, 6B11+CD3+ and 6B11+Vα24+ iNKT cells in 
the MNC fraction (1.12%1.07% vs 0.54% 0.30%; 0.63%0.38% vs 0.56%0.21%; 
0.200.32% vs 0.02%0.02%, d.n.s). No differences were found for NK and CIK cells. 
Although only few data were available we can demonstrate, that higher proportions of 
6B11+/6B11+CD3+/6B11+Vα24+ iNKT cells correlate with adult ALL patients who achieved 
CR and without extramedullary foci. Moreover, CD3-CD161+ NK cells correlated with adult 
ALL patients who achieved CR: No correlations were found for CIK cells. 
 
5.5 Numbers and compositions of iNKT, NK and CIK cells from CLL patients 
compared to healthy probands and their correlations with the prognosis  
 
5.5.1 CLL patients show significantly lower proportions of iNKT, NK and CIK cells in MNC 
compared to healthy MNC 
 
We found significantly*** lower frequencies of CD3+CD56+ CIK cells in MNC of CLL patients 
compared to healthy MNC (0.67%0.73% vs 2.74%1.64%, p<0.0036) and significantly*** 
lower frequencies of CD3+CD161+ CIK cells (0.67%0.84% vs 3.25%1.02%, p<0.000168,  
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Figure 15).  
Figure 15: CIK cell frequencies in healthy- versus CLL-MNC 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of CIK cells and their subsets (CD3+CD56+/MNC and 
CD3+CD161+/MNC) in healthy vs CLL MNC are given. 
 
Moreover, we found significantly*** lower proportions of CD3-CD56+ NK cells (3.27%3.26% 
vs 9.33%4.06%, p<0.00243) and significantly*** lower proportions of CD3-CD161+ NK cells 
in MNC of CLL patients vs healthy MNC (0.45%0.48% vs 2.44%1.20%, p<0.00302, Figure 
16).  
 
Figure 16: NK cell frequencies in healthy- versus CLL-MNC 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of NK cells and their subsets (CD3-CD56+/MNC and CD3-CD161+/MNC) 
in healthy vs CLL MNC are given. 
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Moreover, we found significant* lower frequencies of 6B11+ (0.78%0.47% vs 2.47%3.12%, 
p<0.0828), 6B11+CD3+ (0.46%0.47% vs 0.93%0.72%, p<0.072, Figure 17) and 
6B11+V24+ iNKT cells in MNC from CLL patients vs healthy MNC (0.03%0.03% vs 
0.16%0.27%, p<0.09522). Moreover, lower proportions of 6B11+CD8+ and 6B11+CD161+ 
iNKT cells were found in MNC from CLL patients vs healthy MNC (d.n.s).   
 
Figure 17: iNKT cell frequencies in healthy- versus CLL-MNC 
 
 
 
 
 
 
 
 
 
 
  
Legend: Frequencies of iNKT cells and their subsets (6B11+/MNC, 6B11+CD3+/MNC and 
6B11+CD161+/MNC) in healthy vs CLL MNC are given. 
 
In summary frequencies of 6B11+/ 6B11+CD3+/ 6B11+CD161+/ 6B11+CD8+/ 6B11+Vα24+ 
iNKT, CD3-CD56+/ CD3-CD161+ NK and CD3+CD56+/ CD3+CD161+ CIK cells/ subsets were 
(significantly) lower in CLL MNC than in healthy MNC.  
 
5.5.2 Significantly higher proportions of T and NK cells express 6B11 in CLL patients 
compared to healthy probands 
 
We found significantly*** higher frequencies of CD3+T-cells expressing 6B11 in CLL patients 
compared to healthy controls (11.27%11.83% vs 2.69%2.17%, p<0.00384, Figure 18). 
Furthermore, we found significantly** higher frequencies of for CD4+ cells expressing 6B11 
(7.14%5.90% vs 0.31%0.38%, p<0.00908) and significantly*** higher frequencies of 
CD161+ cells expressing 6B11 in CLL patients vs healthy controls (23.55%20.47% vs 
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4.62%5.97%, p<0.00043, Figure 4D). We did not find significant differences in the numbers 
of CD3+CD161+ CIK cells in the CD3+ T cell fraction and CD8+ T cells expressing 6B11 (d.n.s). 
 
Figure 18: iNKT cell frequencies in the NK and T cell fraction in healthy- versus CLL-MNC 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of iNKT cell subsets in the T cell fraction (6B11+CD3+/CD3+) and in the 
NK cell fraction (6B11+CD161+/CD161+) in healthy vs CLL MNC are given. 
 
In summary, a shift to higher proportions of (CD3+/CD4+) T cells and (CD161+) NK cells 
coexpressing 6B11 was found in CLL patients compared to healthy samples. Like in AML 
patients, but unlike in ALL patients, no differences were found for CIK cells in the CD3+ T cell 
fraction. Unlike AML and ALL patients no differences were found for CD8+ T cells expressing 
6B11. 
 
5.5.3 CLL patients with prognostically favorable subgroups are characterized by higher 
proportions of iNKT, NK and CIK cells 
 
CLL patients with no need vs need for therapy presented with significantly* higher proportions 
of CD3+CD56+ CIK cells in the MNC-fraction (1.07%1.03% vs 0.43%  0.28%, p<0.093, 
Figure 19 left side). We found (n.s) higher frequencies of 6B11+ iNKT cells in the MNC-
fraction of CLL patients with no need vs need for therapy (0.81%0.50% vs 0.73%0.40%, 
Figure 19 middle row). Comparable results were found for 6B11+CD3+ and 6B11+Vα24+ iNKT 
cell proportions in the MNC-fraction of CLL patients with no need vs need for therapy (d.n.s). 
No differences were found for NK cells. CLL patients younger vs older than 60 years presented 
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with significantly* higher frequencies of 6B11+ and 6B11+Vα24+ iNKT cells in the MNC- 
fraction (0.87%0.55% vs 072%0.40%; 0.04%0.03% vs 0.01%0.01%, p<0.0711, Figure 
19 right side). 
 
Figure 19: Prognostic relevance of CIK, NK and iNKT cells for CLL patients - need for 
therapy (yes or no, left side and middle row), allocation to age groups (<60 versus >60 years, 
right side) 
 
 
 
 
 
 
 
 
  
Legend: Relevance of CIK and iNKT cells for prognosis of CLL patients. Frequencies of CIK 
(CD3+CD56+/MNC) and iNKT cells (6B11+/MNC) in patients with no need vs need for therapy 
and iNKT cells (6B11+Vα24+/MNC) in patients <60 vs >60 years are given. 
 
CLL patients with stable vs no stable disease (NCR, relapse or death with disease) presented 
with (n.s) higher percentages of CD3+CD56+ CIK cells and CD3-CD56+ NK cells in MNC-
fraction (0.70%0.79% vs 0.47% 0.23%; 3.40%3.33% vs 3.50%2.64%, Figure 20 left side 
and middle row). Moreover, we could demonstrate significantly** higher frequencies of 6B11+ 
(0.82%0.49% vs 0.47%0.06%, p<0.021) and significantly* higher frequencies of 
6B11+CD3+ iNKT cells in the MNC-fraction of CLL patients with stable CR vs NCR 
(0.49%0.48% vs 0.17%0.09%, p<0.0597, Figure 20 right side). 
In summary, (significantly) higher proportions of 6B11+ iNKT cells correlated with no need for 
therapy, CLL patients younger than 60 years and stable CR. Comparable correlations were 
found for 6B11+CD3+/ 6B11+Vα24+ iNKT subsets. CD3-CD56+ NK and CD3+CD56+ CIK cells 
regularly correlated with stable CR, while only CD3-CD56+ NK cells correlated with no need 
for therapy.  
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Figure 20: Prognostic relevance of CIK, NK and iNKT cells for CLL patients - stable disease 
(yes or no) 
 
 
 
 
 
 
 
 
  
Legend: Relevance of CIK and iNKT cells for prognosis of CLL patients. Frequencies of CIK 
(CD3+CD56+/MNC), NK (CD3-CD56+/MNC) and iNKT cells (6B11+/MNC) in patients with 
stable versus no stable disease are given. 
 
5.6 iNKT, NK and CIK cells and their subtypes increase under the influence of IL-2 and 
after pre-stimulation with DC/ DCleu 
 
It is well known that DC/ DCleu are professional stimulators of T cells, thereby giving rise to 
antileukemic active effector cells after MLC (containing IL-2).  
We generated DC/ DCleu from healthy or leukemic MNC or WB (DCleu were only analysed in 
cases the amount of DC were ≥10%) and achieved the following results:  
‘MNC-healthy’: With ‘Kit D’ we generated Ø 10.79%±2.07%, with ‘Pici 1’ 15.42%±4.97% 
and with ‘Pici 2’ 15.33%±6.09% DC in MNC.  
‘WB-healthy’: With ‘Kit D’ we generated Ø 7.44%±1.28%, with ‘Kit I’ 11.05%±6.82%, with 
‘Kit K’ 8.62%±2.00%, with ‘Kit M’ 8.08%±3.38%, with ‘Pici 1’ 10.50%±2.62% and with ‘Pici 
2’ 9.48%±1.85% DC in WB.  
‘MNC-AML’: With ‘Kit D’ we generated Ø 36.51%±7.33% DC and 6.70%±0.58% DCleu, with 
‘Pici 1’ 23.53%±0.00% DC and 12.63%±0.00% DCleu and with ‘Pici 2’ 19.39%±7.39 DC and 
10,20%±0,00 DCleu in MNC. 
‘WB-AML’: With ‘Kit D’ we generated Ø 6.85%±1.10% DC, with ‘Kit I’ 13.18%±7.43% DC 
and 19.95%±0.00% DCleu, with ‘Kit K’ 10.48%±3.77% DC and 8.11%±2.38% DCleu, with ‘Kit 
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M’ 9.92%±3.93% DC and 13.62%±0.00% DCleu, with ‘Pici 1’ 10.16%±0.00% DC and 
8.98%±0.00% DCleu and with ‘Pici 2’ 12.88%±0.00% DC and 11.39%±0.00% DCleu in WB.  
Pooling all results from the controls without added response-modifiers (‘MNC-healthy’, ‘WB-
healthy’, ‘MNC-AML’, ‘WB-AML’) we found Ø 6.28%±2.09% DC.  
Here we studied, whether iNKT/ NK/ CIK cells (in MNC or WB samples) could contribute to 
improve the overall-antileukemic activity after stimulation with DC/ DCleu. Therefore, we 
stimulated in MLC (prepared with MNC or WB) T cell enriched immune reactive cells with a 
stimulator cell suspension containing DC/ DCleu (MLC
*‘MNC-DC’ or MLC*‘WB-DC’) which were 
generated with different ‘cocktails’. The same setting, but with a stimulator cell suspension 
without pretreatment with ‘cocktails’ (MLC*‘MNC’ or MLC*‘WB’) served as a control. First, we 
quantified these cells before and after MLC with added T cells and IL-2. In a second step, we 
analysed the effect of different ‘cocktail’-generated DC/ DCleu on the composition of immune 
reactive cells after stimulation. Further, we correlated our findings with antileukemic reactivity 
in a context with iNKT, NK, CIK cells and T cell subsets.  
 
5.6.1 In MLC of healthy and AML patients (MLC*’WB-DC’ or only MLC*’WB’) proportions of 
iNKT, NK and CIK cells increase in the presence of IL-2 
 
At start of MLC we found lower total frequencies of iNKT cells and a shift to higher proportions 
of T/ NK cells coexpressing 6B11 in AML patients (n=6) vs healthy WB samples (n=5; Figure 
21A). In a next step we quantified these cells after MLC and found that iNKT cells 
significantly(*)* increased in both AML  and healthy WB-samples after MLC: at start of MLC 
versus after MLC*‘WB’(AML 6B11+/MLC: 4.18%±1.32% vs 8.63%±4.40%, p<0.0745*; healthy 
6B11+/MLC: 4.68%±3.92% vs 12.34%±8.10%, p<0.0305**; healthy 6B11+CD3+/MLC: 
4.60%±3.90% vs 12.11%±8.10%, p<0.0385**; healthy 6B11+CD3+/CD3+: 5.17%±4.63% vs 
31.77%±22.85%, p<0.0732*; Figure 21A vs 21B) and start of MLC versus after MLC*‘WB-DC’ 
(healthy 6B11+/MLC: 4.68%±3.92% vs 13.67%±5.01%, p<0.0323**; healthy 
6B11+CD3+/MLC: 4.60%±3.90% vs 13.03%±4.91%, p<0.0393**; 6B11+CD3+/CD3+: 
5.17%±4.63% vs 21.51%±7.38%, p<0.0093**, Figure 21A vs 21C). 
Pooling all results after MLC*‘WB-DC’ compared to MLC*‘WB’, an astonishing finding was that 
cellular compositions in healthy samples were comparable in both settings (Figure 21B vs 
21C). This could be due to the general influence of IL-2 in MLC.  
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Figure 21: Frequencies of iNKT cells in MLC (WB) at the start of MLC (A), after MLC*’WB’1 (control) (B) and after MLC*’WB-DC’2  
(C) are given.  
 
Legend: Frequencies of iNKT cells before (A) or after (B, C) MLC (WB) are given. T cell enriched immune reactive cells were stimulated with a 
stimulator cell suspension without pretreatment of WB with ‘cocktails’ (1MLC*‘WB’) or with a stimulator-cell-suspension pretreated with ‘cocktails’ 
(2MLC* ‘WB-DC’). ‘Cocktails’ = all DC-generating methods/Kits. 
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Figure 22: Frequencies of CIK/NK cells in MLC (WB) at the start of MLC (A), after MLC*’WB’1 (control) (B) and after MLC*’WB-DC’2 (C) 
are given. 
 
Legend: Frequencies of CIK and NK cells before (A) or after (B, C) MLC (WB) are given. T cell enriched immune reactive cells were stimulated 
with a stimulator cell suspension without pretreatment of WB with ‘cocktails’ (1MLC*‘WB’) or with a stimulator-cell-suspension pretreated with 
‘cocktails’ (2MLC* ‘WB-DC’). ‘Cocktails’ = all DC-generating methods/Kits
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However, in AML cases the proportions of iNKT cells increased after MLC*‘WB-DC’ compared 
to MLC*‘WB’ (Figure 21B vs 21C). Differences were not significant. Comparable results were 
found for MNC (d.n.s.) 
At start of MLC we found lower total frequencies of CIK and NK cells in AML (n=6) vs healthy 
WB-samples (n=5) (Figure 22A). 
In a next step we quantified these cells after MLC and found that CIK and NK cells 
(significantly) increased in both AML and healthy WB-samples after MLC: at start of MLC 
versus after MLC*‘WB’(AML CD3+CD161+/MLC: 1.41%±0.74% vs 3.28%±1.59%, 
p<0.0487**; healthy CD3+CD161+/MLC: 2.35%±2.59% vs 3.30%±2.04%; AML CD3-
CD161+/MLC: 0.15%±0.15% vs 1.62%±1.81%; healthy CD3-CD161+/MLC: 1.41%±2.48% vs 
0.80%±0.86%; Figure 22A vs 22B) and start of MLC versus after MLC*‘WB-DC’ (AML 
CD3+CD161+/MLC: 1.41%±0.74% vs 3.15%±2.13%; healthy CD3+CD161+/MLC: 
2.35%±2.59% vs 4.20%±2.02%; AML CD3-CD161+/MLC: 0.15%±0.15% vs 1.73%±1.98%; 
healthy CD3-CD161+/MLC: AML 1.41%±2.48% vs 0.57%±0.37%; Figure 22A vs 22C). 
Pooling all results after MLC*‘WB-DC’ compared to MLC*‘WB’, an astonishing finding was, that 
cellular compositions in healthy samples were comparable in both settings (Figure 22B vs 
22C). This could be due to the general influence of IL-2 in MLC.
In summary, iNKT as well as CIK and NK cells increased after MLC independent of the 
stimulator cell suspension, what might be explained by a general iNKT, NK and CIK cells 
inducing effect by IL-2. AML samples treated with ‘cocktails’ and used as stimulator cells 
seemed to increase iNKT but not CIK and NK cell frequencies compared to not pretreated 
controls, pointing to an ‘iNKT-inducing influence’ of these different ‘cocktails’.  
 
5.6.2 Highest iNKT frequencies after MLC could be found in cases with DC generation 
conducted with prostaglandin-containing ‘cocktails’ 
 
Studying the influence of different DC/ DCleu, generated with ‘cocktails’, on the frequencies of 
6B11 +iNKT cells after MLC showed that in MNC/ WB samples iNKT cell proportions 
increased in general during the MLC. For each individual patient we defined the best stimulator 
cell source resulting in the ‘highest’ (‘+++’) 6B11+ iNKT cell frequencies after MLC  
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(Ø6B11+/WB: 24.91%±19.61%, Ø6B11+/MNC: 10.98%±7.05%); in ‘high’ (‘++’) 6B11+ iNKT 
cell frequencies (only defined for WB, Ø6B11+/WB: 13.56%±6.59); with a ‘good’ (‘+’) 
frequency of 6B11+ iNKT cells (Ø6B11+/WB: 8.06%±2.77%; Ø6B11+ /MNC: 5.88%±4.42%) 
and with ‘no increase’ (‘-‘) or even in a decrease of iNKT cells (Ø6B11+/WB: 3.94%±2.45%, 
Ø6B11+ /MNC: 0.93%±0.21%). Frequencies were applied for healthy and AML samples. 
Similar distributions were found for 6B11+CD161+ and 6B11+CD3+ iNKT cells.  
  
Figure 23: Frequencies of iNKT cells (6B11+ or 6B11+CD3+ or 6B11+CD161+ iNKT cells) 
after MLC*‘MNC-DC’ and MLC*‘MNC’ are given. 
Healthy ‘MNC’ Kit-D ‘Pici1’ ‘Pici2’ control 
P1418 + +++ - + 
P1421 + + +++ + 
P1422 + +++ + + 
P1425 +++ 
  + 
P1428 + 
 +++ + 
P1429 
 +++ - - 
P1436 
 +++ + +++ 
P1438 +++ + + + 
AML ‘MNC’ Kit-D ‘Pici1’ ‘Pici2’ control 
P1424 -   - +++ 
P1426 +++ + - + 
Legend: Frequencies of iNKT cells (6B11+ or 6B11+CD3+ or 6B11+CD161+) after MLC 
(MNC) are given. T cell enriched immune reactive cells were stimulated with a stimulator cell 
suspension without pretreatment of MNC with ‘cocktails’ (1MLC*‘MNC’) or with a stimulator-
cell-suspension pretreated with ‘cocktails’ (2MLC* ‘MNC-DC’).  ‘+++’ = ‘highest’ counts of 
iNKT-cells; ‘++’ = ‘high’ counts of iNKT-cells, ‘+’ = ‘good’ counts of iNKT-cells, ‘-‘ = ‘no’ 
increase or decrease of iNKT-cells 
 
We could show that especially in cases in that the DC generation was performed with 
prostaglandin-containing (PGE1, PGE2) ‘cocktails’ the percentages of iNKT cells increased the 
most (Kit-D, Kit-K, Kit-M, ‘Pici1’, ‘Pici2’, Figure 23). 
Moreover, we found that in almost every given patient (except P1433) we could select at least 
one of several ‘cocktails’, that increased iNKT proportions – pointing to an effect of a certain 
pretreatment with ‘cocktails’ on the frequencies of iNKT cells in healthy as well as of AML 
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samples. Effects seen in MNC and WB samples from healthy and AML samples were 
comparable (Figure 23 vs 24). Comparable effects were found for CIK cells (d.n.s.).  
 
Figure 24: Frequencies of iNKT cells (6B11+ or 6B11+CD3+ or 6B11+CD161+ iNKT cells) 
after MLC*‘WB-DC’ and MLC*‘WB’ are given. 
Healthy ‘WB’ Kit-D Kit-I Kit-K Kit-M ‘Pici1’ ‘Pici2’ control 
P1420 +++ + + ++ + + ++ 
P1428 + + +++ ++ + ++ ++ 
P1429 ++ + + + ++ + +++ 
P1436       +  +++ + + 
P1438 - - - +++ ++ - + 
AML ‘WB’ Kit-D Kit-I Kit-K Kit-M ‘Pici1’ ‘Pici2’ control 
P1424 +++ - - - - - - 
P1426 ++   + + + + +++ 
P1430 + + +++       ++ 
P1433   -         - 
P1434   +++ +++ ++     + 
P1439       +++     ++ 
Legend: Frequencies of iNKT cells (6B11+ or 6B11+CD3+ or 6B11+CD161+) after MLC 
(WB) are given. T cell enriched immune reactive cells were stimulated with a stimulator cell 
suspension without pretreatment of MNC with ‘cocktails’ (1MLC*‘WB’) or with a stimulator-
cell-suspension pretreated with ‘cocktails’ (2MLC* ‘WB-DC’).  ‘+++’ = ‘highest’ counts of iNKT-
cells; ‘++’ = ‘high’ counts of iNKT-cells, ‘+’ = ‘good’ counts of iNKT-cells, ‘-‘ = ‘no’ increase 
or decrease of iNKT-cells 
 
Moreover, we correlated percentages of 6B11+/ 6B11+CD3+/ 6B11+CD161+ iNKT cells 
(defined as ‘highest’, ‘high’, ‘good’ and ‘no increase’) after MLC in MNC (Figure 23: healthy 
‘MNC’) for each individual sample with the frequencies of DC after culture of healthy MNC 
(n=8) with different ‘cocktails’. We found that samples with the ‘highest’ (Ø6B11+/MNC: 
10.98%±7.05%) frequencies of iNKT cells showed (although not significant) higher 
percentages of DC after the DC-generating-process compared to MLC with ‘no increase’ 
(Ø6B11+ /MNC: 0.93%±0.21%) or even a decrease of iNKT cells (Ø DC-counts: 
12.87%±5.44% vs 9.11%±8.81%; Figure 25).  
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Figure 25: Frequencies of iNKT cells (6B11+ or 6B11+CD3+ or 6B11+CD161+ iNKT cells) 
after MLC*‘MNC-DC’ and MLC*‘MNC’ correlate with DC-values from healthy MNC 
 
 
 
 
 
Legend: Frequencies of DC values in healthy MNC are given. Frequencies are correlated with 
‘+++’ = ‘highest’ counts of iNKT-cells and ‘-‘ = ‘no’ increase or decrease of iNKT-cells (see 
Figure 23+24).  
 
Those correlations were not found for MNC of the two AML-patients we have analysed (d.n.s). 
In a next step, we correlated these values with DC/DC-subtype-values obtained from 5 healthy 
and 6 AML-WB-samples and did not find correlations between DC/ DC subtype frequencies 
and iNKT cells after MLC (d.n.s).   
In summary, differences in iNKT cell compositions after MLC could be found in individual 
samples (healthy or AML) after pretreatment with different ‘cocktails’. Highest percentages 
were found with prostaglandin-containing methods. Together, high frequencies of DC 
correlated with ‘highest’ frequencies of iNKT cells after MLC in MNC of healthy controls, 
while lower percentages of DC correlated with ‘no increase’ or even a decrease of iNKT cells 
after MLC in MNC of healthy controls - however, these correlations were not found for the two 
AML-patients analysed.  
 
5.6.3 Physiological hypoxia does not influence amounts and compositions of iNKT, NK and 
CIK cells compared to normoxic conditions 
 
Under physiological conditions the O2-concentration in PB is lower than the normoxic 21%. 
With some preliminary experiments, we wanted to work out results under physiologically most 
adapted conditions in order to draw first conclusions for the functional relevance on immune-
0%
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20%
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'+++' '-'
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reactive cells: physiological low O2 concentrations could possibly influence the conversion of 
blasts to DCleu and in consequence the composition and reactivity of immune-reactive cells. 
Here we studied whether hypoxic (compared to normoxic) conditions influence the composition 
of iNKT/ NK/ CIK cells after MLC (in WB samples). Results included in this chapter were 
cultured in 6% or 10% O2 or with varying O2-concentrations between 0-17%. For our 
evaluations, all results were pooled. In a first step, we quantified DC-(subtype) proportions in 
healthy WB-samples (n=4) with or without stimulation with three ‘cocktails’ (Kit-I, Kit-K or 
Kit-M). We could show that DC-proportions (overall and mature DC (DCmig)) were not 
significantly different in cases cultured under normoxic vs hypoxic conditions (d.n.s.).  
In a next step, we quantified iNKT, NK and CIK cell proportions after MLC*‘WB-DC’ and 
MLC*‘WB’ under hypoxic vs normoxic conditions. Pooling all results after MLC*‘WB-DC’ we 
found comparable proportions of iNKT, NK and CIK cells after MLC under normoxic vs 
hypoxic conditions (d.n.s.).  
In summary, low O2-culture-concentrations do not seem to have neither a significant impact on 
the generation of DC nor on the amount and composition of iNKT, NK and CIK cells after 
MLC.  
 
5.6.4 iNKT, NK and CIK cells contribute to antileukemic activity  
 
As shown above iNKT cell proportions increase after MLC*‘WB-DC’ or MLC*‘MNC-DC’. Here we 
studied, whether iNKT, NK and CIK cells could contribute to improve the overall-antileukemic 
activity after MLC. In a first step, we quantified these cells and their subtypes in individual AM 
WB samples (precultured with various ‘cocktails’) after MLC (with added T cells and IL-2). In 
a next step, we correlated frequencies of iNKT, NK, CIK cells with the antileukemic activity 
(blast-lysis evaluated with a cytotoxicity (fluorolysis) assay) of the individual WB samples 
from AML patients.   
We found that cases with vs without an antileukemic activity (‘lysis’ vs ‘non-lysis’) were 
characterized by significantly*** increased frequencies of 6B11+ iNKT cells in the total MLC 
(7.25%±4.21% vs 2.60%±0.96%, p<0.0022) and significantly** higher frequencies of 
6B11+CD161+/ 6B11+CD3+ iNKT cells in MLC (3.67%±3.55% vs 1.06%±0.29%, p<0.0083; 
5.10%±2.57% vs 2.12%±1.04%, p<0.0232, Figure 26).  
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Figure 26: iNKT cell frequencies – lysis versus no lysis 
 
 
 
 
 
 
 
 
 
 
  
Legend: Frequencies of iNKT cells after MLC (MNC/WB) are given. T cell enriched immune-
reactive cells with stimulated with a stimulator cell suspension without pretreatment of MNC 
with ‘cocktails’ (1MLC*‘MNC/WB’) or with a stimulator-cell-suspension pretreated with 
‘cocktails’ (2MLC* ‘MNC/WB-DC’) were compared in cases with and without blast lysis. Results 
were obtained with a cytotoxicity (fluorolysis) assay.  
 
However, the subtype compositions of iNKT and CIK cell subsets were comparable in the two 
groups compared (6B11+CD161+/CD161+: 52.63%±24.14% vs 51.34%±9.10%; 
6B11+CD3+/CD3+: 18.45%±15.34% vs 17.25% ±9.79%; CD3+CD161+/CD3+: 
15.08%±14.03% vs 14.88%±5.34%, Figure 27).  
 
Figure 27: Frequencies of iNKT and CIK cell subsets – lysis versus no lysis 
 
 
 
 
 
 
 
 
 
 
  
Legend: Frequencies of iNKT and CIK cells subsets after MLC (MNC/WB) are given. 
MLC*‘MNC/WB’ or MLC* ‘MNC/WB-DC’ were compared in cases with and without blast lysis. Results 
were obtained with a cytotoxicity (fluorolysis) assay.  
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Moreover, significantly* higher proportions of CD3+CD161+ CIK cells in MLC (3.26%±2.35% 
vs 1.85%±0.48%, p<0.0509) and significantly*** increased frequencies of CD3-CD161+ NK 
cells in MLC were found in cases with vs without an antileukemic activity (2.07%±2.13% vs 
0.21%±0.13%, p<0.0023, Figure 28).  
 
Figure 28: CIK and NK cell frequencies – lysis versus no lysis 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of CIK and NK cells after MLC (MNC/WB) are given. MLC*‘MNC/WB’ or 
MLC* ‘MNC/WB-DC’ were compared in cases with and without blast lysis. Results were obtained 
with a cytotoxicity (fluorolysis) assay.  
 
However, significantly* higher proportions of proliferating T-cells (Tprol: CD3
+CD69+/MLC) 
and significantly** higher frequencies of central memory T cells (Tcm: 
CD3+CD45RO+CCR7+/MLC) were found in cases with vs without an antileukemic activity 
(Tprol: 17.56%±7.86 vs 15.29%±2.61%, p<0.0825, Tcm: 9.35%±10.47% vs 2.32%±1.5%, 
p<0.01451, Figure 29). No significant differences were found in the composition of naïve/non-
naïve T cells in the groups compared (d.n.s.).). 
Moreover, we assorted our samples according to their antileukemic activity (‘lysis’ vs ‘non-
lysis’) and evaluated predictive cut-off values for NK/ CIK/ iNKT cells after MLC*‘WB-DC’ and 
MLC*‘WB’. 100% of samples with >4% 6B11+ iNKT cells, with > 4% 6B11+CD3+ iNKT cells 
and with >1.5% 6B11+CD161+ iNKT cells after MLC*‘WB-DC’ and MLC*‘WB’ showed 
antileukemic activity (‘lysis’). Furthermore, 100% of samples with >2.3% CD3+CD161+CIK 
cells and with >1.9% CD3+CD56+ CIK cells after MLC*‘WB-DC’ and MLC*‘WB’ showed 
antileukemic activity. Moreover, 89-100% of samples with >0.4% CD3-CD161+ NK cells and 
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with >1.3% CD3-CD56+ NK cells after MLC*‘WB-DC’ and MLC*‘WB’ showed antileukemic 
activity.  
 
Figure 29: Frequencies of T cell subsets - lysis versus no lysis 
 
 
 
 
 
 
 
 
 
 
 
Legend: Frequencies of T cell subsets after MLC (MNC/WB) are given. MLC*‘MNC/WB’ or MLC* 
‘MNC/WB-DC’ were compared in cases with and without blast lysis.  Results were obtained with a 
cytotoxicity (fluorolysis) assay. Tprol proliferating T-cells (CD69
+CD3+), Tcm central-memory 
T-cells (CD45RO+CCR7+). 
 
Further, we analysed whether the addition of ‘cocktails’ to cultures improves the antileukemic 
activity after MLC compared to controls.  Samples with more lysis compared to controls, were 
defined as improved blast-lysis, samples with less lysis compared to controls as ‘not improved’ 
blast-lysis. Samples with improved blast-lysis showed significantly* higher 6B11+ iNKT cell 
frequencies compared to samples with not improved blast-lysis (7.94%±4.12% vs 
4.39%±3.12%; p<0.0921). Moreover, samples with improved blast-lysis showed (n.s.) higher 
frequencies of 6B11+CD161+- and 6B11+CD3+ iNKT cells compared to samples with not 
improved blast-lysis (4.82%±3.49% vs 1.80%±2.90%; 5.25%±2.13% vs 3.50%±1.84%).  
Furthermore, samples with ‘improved’ blast-lysis showed (n.s.) higher frequencies of 
CD3+CD161+ CIK cells and CD3-CD161+ NK cells compared to samples with not improved 
blast-lysis (3.99%±2.51% vs 2.10%±1.83%; 2.73%±1.95% vs 0.95%±1.87%).  
With one exemplary experiment, we could show that a radiation of stimulator-cells did not 
reduce proportions of T/ iNKT/ NK and CIK cells, however reduced the overall blast-lysis 
compared to un-irradiated settings. This could point to a role of iNKT/ NK and CIK cells beside 
T cells in antileukemic reactions (d.n.s.).   
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In summary in cases with antileukemic blast-lytic activity after MLC not only a T cell 
stimulation was induced, followed by a creation of memory T cells, but also that iNKT, NK, 
CIK cell proportions are significantly increased – pointing to an involvement of these cells in 
antileukemic reactions. Moreover, the presence of increased proportions (above cut-off values) 
of iNKT as well as of CIK and NK cells after MLC might correlate with successful blast-lysis.  
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 Discussion 
 
6.1 Role of T, iNKT, NK and CIK cells in tumor immune surveillance  
 
T, iNKT, NK and CIK cells and their subsets are important mediators of immune responses: T 
cells are known to be activated by tumor- or leukemia antigen-presenting DC and – as shown 
exemplarily by our DC/ DCleu ex vivo strategies - their anti-tumor functionality can be improved 
by DCleu.
9. Teff-em enable – in case of a secondary challenge - a very quick and immediate 
secondary immune response, while Treg are able to downregulate immune responses – important 
to inhibit autoaggressive immune reactions – but also in a context to downregulate antitumor 
responses.9,10 In contrast to T cells, iNKT , NK  and CIK cells react quickly to an immunological 
threat by secreting cytokines and chemokines 4,30 and kill tumor cells without prior activation 
and, unlike T  and iNKT cells, NK and CIK cells don’t recognize target cells by a TCR 5. iNKT 
cells can produce a variety of chemokines and cytokines like IFN-, IL-4/-2/-12, TNF-, TGF-
ß and GM-CSF that in consequence activate different cells like DC, NK cells, CD4+/CD8+ T 
cells, but also Treg.
31,32 A previous study could show that all subsets of iNKT cells produce 
almost the same amounts of IFN- and TNF-, while IL-4 is mainly produced by PB CD4+ 
iNKT cells.13 Moreover, iNKT cells show a strong cytolytic potential and can directly kill tumor 
cells as they express granzyme-B, Perforin and FasL.4,31 Therefore, it might be promising to 
use or even to increase the antileukemic potential of NK, CIK cells and especially iNKT cells 
to enhance the patients’ anti-tumor immune response.   
 
6.2 Methods to detect iNKT, NK and CIK cells  
 
The identification and quantification of iNKT cells (in healthy blood samples) is known to be 
difficult due to their low frequency as well as missing marker (-combinations). Previous 
methods using CD1d tetramers or the combination of V24-/V11-antibodies did not yield the 
necessary specific results.13 Therefore, the first aim of our study was to develop a highly specific 
iNKT cell detection panel for the quantification of iNKT cells and subsets in healthy, but also 
to be used for leukemia patients. Furthermore, we compared strategies and markers to detect 
and quantify NK and CIK cells and their subsets in healthy, but especially in leukemic patients. 
A previous study performed with healthy samples could show that a new moAb (clone 6B11-
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PE) can recognize the invariant CDR3 loop of the Vα24Jα18-TCR rearrangement on the cell 
surface and can be used to specifically characterize iNKT cells in combination with anti-CD3.13 
In our current study, we also used 6B11-PE, but also 6B11-FITC (purchased from different 
companies) to characterize and define iNKT cells. In previous studies11,13, only 6B11-PE was 
used for analysis, but not 6B11-FITC. We found (significantly) higher proportions of iNKT 
cells detected with 6B11-FITC compared to 6B11-PE in AML, ALL, CLL patients. The 
proportions of iNKT cells detected with 6B11-FITC compared to 6B11-PE were (significantly) 
lower in healthy samples. Moreover, 6B11-FITC-stainings seemed to yield varying results in 
several stainings, whereas 6B11-PE-stainings showed stable and precise results for iNKT 
detection. It is well known, that moAbs can react and bind differently to their targets – 
depending not only on the selected clones, but also on the purchasing companies, the 
fluorochromes used or the combination with partner moAbs in a panel 33. In order to exclude 
these variations, we focused mainly on 6B11-PE results in our setting.  
Co-expression analyses of 6B11 with myeloid-(e.g.: CD33, CD34, CD117) or lymphoid (e.g.: 
CD1a, CD5, CD7, CD10, CD19, CD20) markers on blasts from malignant myeloid and 
lymphoid cell lines showed, that 6B11 was not expressed on myeloid or B-lymphoid blasts. 
However, we found a low expression of 6B11 on T-linear cells of the Jurkat cell line. Since we 
do not know, whether this cell line has a V24-/V11-rearrangement, typical for iNKT cells 
we cannot decide whether this expression is ‘aberrant’ on this cell line or specific. In general, 
our results show that the 6B11-PE-marker, but not 6B11-FITC, can be regarded as a very 
specific marker to detect iNKT cells without cross-reactivity or aberrant expression on leukemic 
cells. Previous studies did not analyse whether 6B11 is aberrantly expressed on leukemic blasts 
and if 6B11-FITC is specific for iNKT cells analyses. Thereby, we can confirm preliminary 
findings of other groups that the detection of iNKT cells with 6B11 alone or in combination 
with subtype markers is very precise, as 6B11 specifically recognizes the CDR3 loop of the 
invariant TCR of CD1d-restricted iNKT cells.13  
It is known, that the iNKT cell population consists of different subsets with diverse phenotypic 
and functional characteristics that can be subdivided according to their expression of surface 
molecules, receptors, effector functionality or tissue localization.4 In a former study it was 
shown that 6B11 could be used in combination with further T (CD27, CD28, CD45RA, 
CD45RO) and NK cell markers (CD16, CD56, CD161) to analyse iNKT subsets.13 Moreover, 
iNKT cells were characterized by the combination of CD1d and CD3 or the combination of 
Vα24 and Vβ11. The percentage of iNKT cells expressing CD4 or CD8 was evaluated in a 
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region comprising 6B11+CD3+ iNKT cells. Like the previous study, we used 6B11 in 
combination with CD3, CD45R0 and CD161. Moreover, we included the combinations of 6B11 
with CD1d, Vα24, CD4 or with CD8. This means that we evaluated the expression of T cell 
(CD1d, CD3, CD45RO, V24) and NK cell markers (CD161) on 6B11+ iNKT cells and divided 
them into ‘T cell-like’ and ‘NK cell-like’ iNKT subsets. We are the first group, that defined ‘T 
cell-like’ iNKT subsets as CD3+6B11+-, CD4+6B11+-, CD8+6B11+-, Vα24+6B11+-, 
CD1d+6B11+-, CD45RO+6B11+- and CD45RO-6B11+ iNKT cells.  
Classically, iNKT cells have been identified with CD1d-tetramers loaded with -GalCer, but 
this method could lead to an overestimation of iNKT cells as some T cell subsets also express 
CD1d.13 This study did not find significant differences in 6B11+ iNKT cells compared to 
CD3+6B11+ iNKT cells or CD3+CD1d+ iNKT cells in healthy samples. Although we did not 
combine CD1d with CD3, but with 6B11, we could also show that frequencies of 6B11+CD3+ 
and 6B11+CD1d+ iNKT cells were comparable in healthy samples. We could show in addition 
that frequencies of 6B11+CD3+ and 6B11+CD1d+ iNKT cells were similar in AML, ALL and 
CLL samples. Unlike the previous study 13, we detected higher numbers of 6B11+ iNKT cells 
compared to 6B11+CD3+ and 6B11+CD1d+ iNKT cells in healthy samples as well as in AML, 
ALL and CLL samples. 
Using CD3-/Vα24-antibodies, we could demonstrate specific results and detected lower 
frequencies of Vα24+6B11+ iNKT cells compared to CD3+6B11+ iNKT subsets in healthy as 
well as in AML, ALL and CLL patients. These findings are consistent with a previous study, 
which found three times more CD3+6B11+ iNKT cells compared to CD3+Vα24+Vβ11+ iNKT 
cells in healthy adult and children’s samples.11 However, this group combined Vα24 with CD3 
and Vβ11, while we combined Vα24 with 6B11. Unlike these results, another group found 
similar proportions of CD3+6B11+ iNKT cells and Vα24+Vβ11+ iNKT cells in healthy 
controls.13 However, this group used the combination of Vα24 and Vβ11 without combining it 
with CD3. These differences may be explained by the fact, that different combinations of Vα24 
with CD3, Vβ11 or 6B11 were used for iNKT cell detection. Furthermore, the results or our 
group and Bienemann may be explained by the fact that the invariant α-chain of the TCR 
sometimes binds with other ß-chains than Vβ11, which could lead to an underestimation of 
iNKT cells.11  
Both Type I iNKT cells and Type II iNKT cells, are divided into CD4+, CD4-CD8-, CD8+ 
and CD8+ iNKT cells, with higher proportions being CD4+, lower proportions being CD4-
CD8- and only a few cells CD8+ or CD8+, which could only be found in humans but not 
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in mice.4 Unlike previous studies, we combined 6B11 with CD4 and CD8 for subtype analyses. 
We can confirm that the majority of 6B11+ iNKT cells coexpresses CD4+ and the minority CD8+ 
in healthy samples. We can add as a new finding in addition that higher proportions of 
6B11+CD4+ iNKT cells and lower proportions of 6B11+CD8+ iNKT cells were also found in 
AML, ALL and CLL- patients. A previous study suggested that CD4+ iNKT cells produce both 
Th1 and Th2 cytokines, whereas CD4- iNKT cells tend to produce mainly Th1 cytokines.31 
However, another study found that CD4+, CD4- and CD8+ iNKT cells produced similar amounts 
of IFN-γ and TNF-α, but CD4+iNKT-cells produced significantly more IL-4.13 In our patients’ 
cohort, we had not further analysed the functional role of CD4 and CD8 expressions on iNKT 
cells. However, we suggest to combine 6B11 with CD4 and CD8 to analyse the diffences 
between 6B11+CD4+, 6B11+CD4-, 6B11+CD8+ and 6B11+CD8- iNKT cells.   
Consistent to a previous study we found that the majority of iNKT cells is CD45RO+6B11+, 
while the minority is CD45RO-6B11+, what could be interpreted as iNKT cells with a memory-
effector-phenotype.13  
We defined ‘NK-like’ iNKT cells as CD161+6B11+ iNKT cells and found lower proportions of 
CD161+6B11+ iNKT cells compared to 6B11+ iNKT cells and 6B11+CD3+ iNKT cells (‘T-like’ 
iNKT cells). A previous study showed different NK cell markers expressed by iNKT cells and 
demonstrated that the majority of iNKT cells expressed CD161, while only a minority 
expressed CD56 and CD16. Furthermore, this study showed that CD161 was expressed on 
significantly higher frequencies of CD8+- or double negative (DN) iNKT cells compared to 
CD4+ iNKT cells. CD161 (KLRB1) is a C-type lectin receptor expressed on human NK cells, 
but also on iNKT and T cell subsets – especially on subgroups found in liver and gut.13-15,18 In 
humans, the CD161 receptor interacts with its ligand LLT1 and suppresses the cytotoxic 
potential of NK cells. Moreover, it was shown that an infection with cytomegalovirus (CMV) 
leads to decreased expression of CD161 on NK cells.34   
In conclusion, we suggest that the most precise detection of iNKT cells should be based on 
6B11-PE alone or in combination with CD3- and CD161-moAbs. Moreover, we found new 
detection methods for iNKT cells/subsets using 6B11 in combination with CD1d, Va24, CD4 
or CD8. Furthermore, we could demonstrate that 6B11 can be used to analyse iNKT cells of 
leukemia patients, knowing that there is no aberrant expression of 6B11 on blasts. Our results 
confirm the heterogeneity of iNKT cells, as we could show that there are various ‘T cell-like’- 
and ‘NK cell-like’ iNKT subsets. This highlights that the iNKT cell population consists of 
several phenotypically and potentially functionally different subsets with diverse surface 
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markers. A previous study could demonstrate that neonatal CD4+, adult CD4+ and adult CD4- 
iNKT cells are phenotypically diverse and show different effector/memory T cell markers and 
NK cell markers. Neonatal CD4+ iNKT cells show a more naïve phenotype and can be modified 
more easily in their capacity to acquire Th1- or Th2-like functions compared to adult iNKT 
cells, which are mainly resistant to functional reprogramming, but show higher cytotoxic 
functions.35  
To detect NK and CIK cells, we used recommended combinations of CD3- with CD161- or 
CD56-moAbs. NK cells were defined as CD3-CD56+- or CD3-CD161+cells and CIK cells were 
defined as CD3+CD56+- or CD3+CD161+cells. Both combinations detect similar amounts of 
NK- and CIK cells in healthy controls. However, CD56 is known to be aberrantly expressed on 
blasts of certain AML-subtypes and correlates with a worse prognosis.36 In these cases, NK 
cells cannot be evaluated with a CD56-marker. We recommend using the CD161-moAb to 
quantify NK cells in cases with aberrant expression of CD56. Therefore, CD161 can be 
regarded as a better NK and CIK cell marker for leukemic patients with aberrant CD56 
expression.  
In conclusion, we suggest that NK and CIK cells can always be detected with the combination 
of CD3- with CD161-moAbs and with CD3- and CD56-moAbs in cases without aberrant 
expression of CD56. The potential functional differences in these subsets, however, should be 
evaluated. 
 
6.3 iNKT, NK and CIK cells in AML, ALL and CLL patients compared to healthy 
samples 
 
The present study shows that AML, ALL as well as CLL patients’ MNC are characterized by 
(significantly) lower frequencies of CIK cells (CD3+CD56+ or -CD161+), NK cells (CD3-
CD56+ or -CD161+) and iNKT cells (6B11+, 6B11+CD3+ or -CD8+ or -CD161+ or -V24+) 
compared to healthy donors. This could be confirmed by another group that demonstrated 
significantly lower median values of NK cells, NKT and iNKT cells in AML patients compared 
to healthy donors’ PB (cells/L: 303.47 vs 101.54; 55.86 vs 21.85; 0.515 vs 0.0814).7 However, 
this group did not compare values of CIK cells in AML patients vs healthy and did not consider 
different NK and iNKT subsets: NK and NKT cells were detected with CD3 and CD16/ 56 and 
iNKT cells with CD3 in combination with Vα24 and Vβ11. 7. In general, these findings can be 
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expected due to the displacement of immune-reactive cells by uncontrolled proliferating and 
expanding blasts.  
In summary, we could show that a high blast-load in AML, ALL or CLL patients directly 
correlated with low frequencies of iNKT, NK and CIK cells. Therefore, the majority of iNKT, 
NK and CIK cells are displaced by blasts in AML, ALL and CLL patients.  
An interesting finding was, that – although proportions of iNKT, NK and CIK cells were 
comparable in leukemic patients, their subtype composition was different in leukemic patients 
compared to healthy donors showing a shift to (significantly) higher frequencies of T and NK 
cells co-expressing 6B11 in AML, ALL and CLL patients compared to healthy donors. This 
might suggest that certain T/ NK derived iNKT cells in leukemic patients might either be 
subtypes with downregulated antileukemic functionality or could be special subsets that could 
be triggered in antileukemic reactivity.  
In summary, we present the new finding that proportions of iNKT, NK and CIK cells were 
significantly lower in AML, ALL and CLL patients and compared to healthy donors. Their 
subset compositions as well as iNKT subsets were comparable in AML, ALL and CLL patients. 
We can demonstrate in addition to findings in the literature a shift to higher proportions of T 
and NK cells expressing 6B11 in AML, ALL and CLL patients compared to healthy donors, 
what might point to comparable mechanisms in leukemic diseases, that favor the extension of 
subsets in these diseases and what might help to develop new iNKT, NK and CIK cell based 
immune therapeutic strategies for leukemia patients.  
 
6.4 Prognostic relevance of iNKT, NK and CIK cells in AML, ALL and CLL patients 
 
A previous study could show that the overall number of iNKT cells in AML patients is an 
important prognostic factor as iNKT cell proportions >0.2 cells/L are associated with 
favorable survival.7 Furthermore, this study could demonstrate that a lower number of iNKT 
cells in PB in combination with higher proportions of CD4+ and CD8+ T cells in BM at 
diagnosis is characterized by a lower overall survival (OS) in AML patients. Another study 
could demonstrate that a high expression of NKp30/NKp46 on CD16+ NK cells in elderly AML 
patients correlated with leukemia-free and better OS. 37 Moreover, previous studies pointed out 
that CIK cells (especially CD3+CD56+) show strong cytotoxic potential, e.g. against 
leukemia4,30, but did not correlate the frequencies of CIK cells with survival or favorable 
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prognosis for leukemia patients. With our results, we confirm these findings and can add in 
addition that higher percentages of iNKT, NK and CIK cells correlate with the allocation of 
patients to diverse prognostically more favorable subgroups not only in AML, but also in ALL 
and CLL.  
We could show that higher frequencies of iNKT cells in leukemic patients correlate with 
prognostically better subsets in AML, adult ALL and CLL patients. AML patients with 
favorable (versus adverse) NCCN risk score showed higher percentages of 6B11+-, 
6B11+CD161+- and 6B11+Va24+ iNKT cells. Moreover, AML and CLL patients younger 
(versus older) than 60 years showed higher numbers of 6B11+-, 6B11+CD161+-, 6B11+CD3+- 
and 6B11+Va24+ iNKT cells. AML patients with primary (versus secondary) AML showed 
higher frequencies of 6B11+- and 6B11+CD3+ iNKT cells. Furthermore, AML and adult ALL 
patients without (versus with) extramedullary foci showed higher frequencies of 6B11+-, 
6B11+CD3+-, 6B11+CD161+- and 6B11+Va24+ iNKT cells. Moreover, adult ALL patients 
achieving CR after GMALL induction chemotherapy (versus NCR) and CLL patients with no 
need (versus need) for therapy showed higher frequencies of 6B11+-, 6B11+CD3+- and 
6B11+Va24+ iNKT cells. AML and CLL patients with stable CR (versus no stable CR: relapse 
or death by disease) showed (significantly) higher percentages of 6B11+-, 6B11+CD3+- and 
6B11+CD161+ iNKT cells, however, one patient had died from pneumonia. This data can 
confirm previous findings7,37,38 that low frequencies of iNKT cells can be correlated with worse 
prognosis and worse overall survival. In contrast to previous studies and our results, another 
study found that lower frequencies of NK and NK like T cells correlated with higher survival 
in AML patients, while higher frequencies were correlated with poor survival.7,37,38  
Moreover, we could show that higher frequencies of NK cells in leukemia patients correlate 
with prognostically better subsets in AML, adult ALL and CLL patients. AML patients without 
(versus with) extramedullary foci showed (significantly) higher frequencies of CD3-CD56+ NK 
cells. Moreover, adult ALL patients, who had achieved CR after GMALL induction 
chemotherapy, showed higher numbers of CD3+CD161+ NK cells. Furthermore, AML and CLL 
patients, who stayed in stable CR (versus no stable CR) showed higher amounts of CD3-
CD161+ and CD3+CD56+ NK cells. Consistent to previous studies,7,37,38 our data show that 
higher percentages of NK cells can be correlated with better prognosis and stabilization of 
disease. In contrast to a previous study, we could not correlate low frequencies of NK cells with 
better survival.7,37,38 
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We can add in addition, that higher frequencies of CIK cells in leukemia patients correlate with 
prognostically better subgroups in AML and CLL patients. AML patients who achieved CR 
(versus NCR) and CLL patients with no need for initial therapy (versus need for initial therapy) 
showed (significantly) more CIK cells. Moreover, AML as well as ALL patients without 
extramedullary foci presented with significantly more CIK cells. Furthermore, AML and CLL 
patients, who stayed in stable CR (versus no stable CR), showed higher numbers of 
CD3+CD161+ and CD3+CD56+ CIK cells. Consistent to previous studies,4,30 these data might 
point to an antileukemic reactivity of CIK cells –leading to stabilized disease.  
We conclude that higher frequencies of iNKT, NK as well as CIK cells can be regarded as a 
favorable prognostic factor for AML, adult ALL and CLL patients. For the future, we 
recommend to perform subtype-analyses of iNKT, NK as well as CIK cells in more detail to be 
able to allocate defined subtypes to prognostic groups. Moreover, we recommend multifactorial 
statistical analyses to work out the role of cellular partners involved in the mediation of anti-
leukemic reactions and better prognosis for individual pts in more detail. 
 
6.5 iNKT, NK and CIK cells contribute to anti-tumor and anti-leukemic activity  
 
A previous study has shown that iNKT cells are important mediators in tumor-protection, as 
reduced frequencies of iNKT cells were correlated with a variety of cancers and increased 
frequencies of iNKT cells were related with favorable response to therapy.39 Another study 
showed, that NK and CIK cells have cytotoxic potential against leukemia and other cancers.30,40-
42  
In the current study, we could show in general that higher proportions of iNKT, NK and CIK 
cells and higher frequencies of proliferating T cells and Tcm correlated with antileukemic 
activity (blast-lysis). Moreover, we could show (although only with one exemplary experiment 
up to now) that radiation of stimulator-cells did not reduce proportions of T, iNKT, CIK and 
NK cells, but reduce the overall blast lysis of (stimulator-cell-activated) effector cell-mediated 
antileukemic activity compared to unradiated settings - what could be explained by a functional 
knockout of these T, iNKT, CIK and NK cells and therefore point to their antileukemic 
contribution. Consistent, a previous study has shown that in knockout experiments in mice 
absence of iNKT cells was correlated with tumor-growth and poor survival, while a transfer of 
iNKT cells into mice could reduce tumor growth.39 All of these results emphasize the relevance 
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of iNKT, CIK and NK cells in antileukemic reactions. More studies have to be performed to 
work out the specific role of these cell fractions in the mediation of antileukemic reactions. To 
further analyse the function of different iNKT, CIK or NK cells and their subtypes we 
recommend performing e.g. blocking experiments knocking out certain cellular subtypes and 
correlating results with antileukemic function. 
With an attempt to evaluate the predictivity of iNKT, CIK and NK cell frequencies we defined 
cut-off values: We could show that cases presenting with higher values of iNKT (subtypes) or 
CIK or NK cells were characterized by a higher chance to belong to the group with 
‘antileukemic activity’.  
In summary, we suggest to define and applicate cut-off values for iNKT, CIK and NK cells and 
their subtypes for leukemia-pts in the future to enable a refined estimation of prognosis  
 
6.6 Induction of iNKT, NK and CIK cells after stimulation with DC/ DCleu 
 
It was already shown that a crosstalk between NK cells and DC improves antitumor reactions. 
Recently, details about the mechanisms behind the increase of antitumor-reactivity (e.g. 
pathogen-associated molecular patterns or cytokines) have been detected.39,43 Moreover 
cytokines, cellular factors, antibodies promote NK cell activations and DC-NK crosstalk  
establishing a microenvironment which enables antitumor reactions.44,45 Moreover, a crosstalk 
between  CIK cells and DC has been reported recently, demonstrating an influence of a DC 
stimulation on the phenotype as well as antileukemic cytotoxicity of CIK cells.46 Recently a 
crosstalk between DC and iNKT cells has been shown (mediated e.g. by chemokine receptor-
expression), leading to an amplification of anti-tumor-immune-reactions.4,47  
With our data, we contribute that iNKT cells not only respond to a stimulus with IL-2, but in 
addition are significantly expanded in cases with previous treatment of AML-or healthy MNC/ 
WB with ‘cocktails’. Comparable phenomena were found for CIK cells. These finding might 
point to an induction of these cell-populations by DC/ DCleu-stimulation.  
Moreover, we can add important new data to a previous study that highlighted three possible 
mechanisms of antitumor-reactivity mediated by iNKT cells: indirect cytotoxicity, direct 
cytotoxicity and modulation of the tumor microenvironment. ‘Indirect cytotoxicity’ says that 
iNKT cells and DC stimulate each other by TCR/CD1d and CD40/CD154 interactions leading 
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to a release of cytokines and increased antitumor activity of other effector cells.39,43 Our data 
might support this theory as we could show that ‘highest’ iNKT cell frequencies were correlated 
with higher DC – pointing to a co-activation between iNKT cells and DC.  
We can add that the highest 6B11+ iNKT and CIK values were found after culture in 
prostaglandin-containing ‘cocktails’. This could point to a special effect of these ‘cocktails’ on 
the allocation and recruitment of iNKT and CIK cells – resulting in an improved antileukemic 
activity- up to now an effect of Prostaglandin E2 on the maturation of DC has been shown.
19,29 
Alternatively, it might be discussed, that ‘only’ the 6B11- or CD56-antigens are upregulated on 
T and NK cells, however without expansion of functionally reactive iNKT and CIK cell 
populations.  
 
6.7 Physiologic culture conditions (hypoxia, WB) do not have an impact on the 
generation of DC nor on the amount and composition of iNKT, NK or CIK cells 
 
Preliminary experiments with MNC/ WB cultured under hypoxic vs normoxic conditions did 
not yield an impact on the generation of DC nor on the frequencies and composition of iNKT, 
NK and CIK cells after MLC. Although more experiments have to be performed we can assume 
that working under normoxic conditions yields ‘physiological’ data.  
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 Conclusions 
 
In conclusion, we recommend to regularly evaluate proportions of iNKT, NK and CIK cells 
and include specific markers in diagnosis-panels (based on 6B11/ CD161/ CD56/ CD3-
antibodies) in AML, ALL and CLL for quantitative, qualitative and prognostically relevant 
estimation of individual patients’ antileukemic potential. Detection of iNKT cells should be 
based on 6B11-(PE)-staining alone or in combination with (especially) CD3 and CD161; NK 
and CIK cell detection should be based on the combination of CD3 with CD161 or with CD56 
(in cases without aberrant expression of CD56). As we could demonstrate a shift to higher 
proportions of T and NK cells expressing 6B11 in AML, ALL and CLL patients compared to 
healthy donors, we suggest that mechanisms behind these subtype extensions have to be studied 
in detail. These findings might be considered in the development of iNKT-based 
immunotherapies.  
Considering that higher frequencies of iNKT, NK and CIK cells correlate with prognostically 
better subgroups and with antileukemic activity (blast lysis) in AML, adult ALL and CLL 
patients, high amounts of iNKT, NK and CIK cells can be regarded as a favorable prognostic 
factor in leukemic patients.  
Moreover, proportions of iNKT and CIK cells increase under stimulation of MLC with IL-2 
and particularly after culture with (prostaglandin-containing-) DC/ DCleu-inducing ‘cocktails’. 
These findings not only point to a cross-talk between these immune reactive cells with DC, but 
in addition a correlation with an improved antileukemic reactivity. In conclusion, ‘cocktails’ 
not only activate antileukemic T cells, but also iNKT and CIK cells and improve the 
antileukemic activity. Inclusion of Prostaglandin-containing DC/ DCleu-generating methods 
might be especially promising in the recruitment of antileukemic active immune reactive cells. 
Although the quantification of these small cell populations (using selected markers and special 
gating-strategies in flow cytometric settings) has to be performed from experienced groups and 
the contribution of these cell populations to antileukemic reactions should not be 
underestimated.  
Novel immunotherapeutic protocols in the treatment of pts with leukemia should be designed, 
that include the quantification of iNKT, NK and CIK cells and their subtypes in diagnostic 
panels. Moreover, the role of iNKT, NK and CIK cells in DC/ DCleu-triggered antileukemic 
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reactions in AML patients should be studied in detail and probably be included in 
immunotherapeutic protocols against AML.  
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